

CONFERENCE REPORTS AND EXPERT PANEL



ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies

Giacomo Grasselli^{1,2*}, Carolyn S. Calfee³, Luigi Camporota^{4,5}, Daniele Poole⁶, Marcelo B. P. Amato⁷, Massimo Antonelli^{8,9}, Yaseen M. Arabi^{10,11,12}, Francesca Baroncelli¹³, Jeremy R. Beitler¹⁴, Giacomo Bellani^{15,16}, Geoff Bellingan¹⁷, Bronagh Blackwood¹⁸, Lieuwe D. J. Bos¹⁹, Laurent Brochard^{20,21}, Daniel Brodie²², Karen E. A. Burns^{21,23,24,25}, Alain Combes^{26,27}, Sonia D'Arrigo⁸, Daniel De Backer²⁸, Alexandre Demoule^{29,30}, Sharon Einav³¹, Eddy Fan²¹, Niall D. Ferguson^{32,33}, Jean-Pierre Frat^{34,35}, Luciano Gattinoni³⁶, Claude Guérin^{37,38}, Margaret S. Herridge³⁹, Carol Hodgson^{40,41}, Catherine L. Hough⁴², Samir Jaber⁴³, Nicole P. Juffermans⁴⁴, Christian Karagiannidis⁴⁵, Jozef Kesecioglu⁴⁶, Arthur Kwizera⁴⁷, John G. Laffey^{48,49}, Jordi Mancebo⁵⁰, Michael A. Matthay⁵¹, Daniel F. McAuley^{18,52}, Alain Mercat⁵³, Nuala J. Meyer⁵⁴, Marc Moss⁵⁵, Laveena Munshi⁵⁶, Sheila N. Myatra⁵⁷, Michelle Ng Gong^{58,59}, Laurent Papazian^{60,61}, Bhakti K. Patel⁶², Mariangela Pellegrini⁶³, Anders Perner⁶⁴, Antonio Pesenti^{1,2}, Lise Piquilloud⁶⁵, Haibo Qiu⁶⁶, Marco V. Ranieri^{67,68}, Elisabeth Riviello⁶⁹, Arthur S. Slutsky^{21,24}, Renee D. Stapleton⁷⁰, Charlotte Summers⁷¹, Taylor B. Thompson⁷², Carmen S. Valente Barbas^{73,74}, Jesús Villar^{24,75,76}, Lorraine B. Ware⁷⁷, Björn Weiss⁷⁸, Fernando G. Zampieri^{79,80}, Elie Azoulay⁸¹ and Maurizio Cecconi^{82,83} on behalf of the European Society of Intensive Care Medicine Taskforce on ARDS

© 2023 The Author(s)

Abstract

The aim of these guidelines is to update the 2017 clinical practice guideline (CPG) of the European Society of Intensive Care Medicine (ESICM). The scope of this CPG is limited to adult patients and to non-pharmacological respiratory support strategies across different aspects of acute respiratory distress syndrome (ARDS), including ARDS due to coronavirus disease 2019 (COVID-19). These guidelines were formulated by an international panel of clinical experts, one methodologist and patients' representatives on behalf of the ESICM. The review was conducted in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement recommendations. We followed the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to assess the certainty of evidence and grade recommendations and the quality of reporting of each study based on the EQUATOR (Enhancing the QUALity and Transparency Of health Research) network guidelines. The CPG addressed

*Correspondence: giacomo.grasselli@unimi.it

¹ Department of Anesthesia, Critical Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
Full author information is available at the end of the article

Giacomo Grasselli, Carolyn S. Calfee and Luigi Camporota contributed equally and should be all considered first authors.

Jordi Mancebo deceased on August 2022.

21 questions and formulates 21 recommendations on the following domains: (1) definition; (2) phenotyping, and respiratory support strategies including (3) high-flow nasal cannula oxygen (HFNO); (4) non-invasive ventilation (NIV); (5) tidal volume setting; (6) positive end-expiratory pressure (PEEP) and recruitment maneuvers (RM); (7) prone positioning; (8) neuromuscular blockade, and (9) extracorporeal life support (ECLS). In addition, the CPG includes expert opinion on clinical practice and identifies the areas of future research.

Keywords: Acute hypoxemic respiratory failure, Acute respiratory distress syndrome, Mechanical ventilation, Extracorporeal membrane oxygenation, Prone position, Non-invasive ventilation, Prognosis, Practice guidelines

Introduction

Acute respiratory distress syndrome (ARDS) is the term applied to a spectrum of conditions with different etiologies which share common clinical-pathological characteristics including: (1) increased permeability of the alveolo-capillary membrane, resulting in inflammatory edema; (2) increased non-aerated lung tissue resulting in higher lung elastance (lower compliance); and (3) increased venous admixture and dead space, which result in hypoxemia and hypercapnia [1]. Over the last 55 years, ARDS definitions have focused primarily on the syndrome's radiological appearance and on the severity of the oxygenation defect (e.g., $\text{PaO}_2/\text{FiO}_2$ ratio), which reflect both the original description of the syndrome [2] and its conceptual understanding [1]. The current definition, the definition of Berlin [3], implies that at time of diagnosis the patient receives at least 5 cmH_2O of positive end-expiratory pressure (PEEP). Formally, patients not receiving positive pressure can thus not be considered as suffering from ARDS. Nevertheless, a lot of patients with AHRE, especially when due to bacterial or viral pneumonia or in case of septic shock, have the same disease and are thus also considered in this guideline.

ARDS accounts for ~10% of admissions to intensive care unit (ICU) and 23% of ventilated patients, with mortality up to 45% in the severe category [4]. The recognition that patients with ARDS are susceptible to additional lung injury induced by mechanical ventilation (ventilator-induced lung injury, VILI) [5] has led to lung-protective strategies designed to reduce total stress (transpulmonary pressure) and strain (the ratio between tidal volume and functional residual capacity) on the aerated lung tissue [6]. These strategies include lower tidal volume and plateau pressure to protect the 'baby lung' [7]; the use of PEEP and lung recruitment maneuvers (RM) to reduce the amount of non-aerated lung; and ventilation in prone position to increase lung homogeneity, improve ventilation/perfusion ratio and lung/chest wall shape matching, reduce stress and strain, and decrease the risk of VILI [8]. Ventilation in the prone position improves outcomes in patients with moderate-to-severe ARDS [9, 10].

Concomitantly, clinicians and investigators alike have sought to avoid invasive ventilation altogether for

patients with early acute hypoxemic respiratory failure (AHRF) using non-invasive respiratory support modalities (e.g., non-invasive ventilation, high-flow nasal oxygen). These therapies seek to improve oxygenation and unload respiratory muscles, thereby reducing inspiratory effort and the risk of patient-self-inflicted lung injury (P-SILI) [11], and allow time for the underlying disease to be treated without the need for sedation and tracheal intubation. For patients with more severe disease, VILI [5] can be theoretically reduced with extracorporeal support techniques which allow partial or total oxygenation and/or carbon dioxide removal and a significant reduction in ventilator mechanical power [12].

The aim of these guidelines is to review and summarize the literature published since the last clinical practice guideline (CPG) of the European Society of Intensive Care Medicine (ESICM) [13] across different aspects of ARDS and AHRE, including ARDS due to coronavirus disease 2019 (COVID-19) in ICU. The scope of this CPG is limited to adult patients and to non-pharmacological respiratory support strategies (except for neuromuscular blockers, which are adjuncts to mechanical ventilation). The document combines a methodologically rigorous evaluation of clinical studies with expert opinion on the respiratory management of patients. This work did not include a cost-effectiveness analysis.

Methods

Topic and panel composition

These guidelines were formulated by an international panel of experts on behalf of the ESICM and address three broad topics within ARDS: (1) definition; (2) phenotyping, and (3) respiratory support strategies. The ESICM Executive Committee selected these three topic areas and nominated three chairpersons (CC, LC, GG) and one methodologist (DP), who arranged the guidelines into nine domains of investigations: (1) definition; (2) phenotyping; (3) high-flow nasal cannula oxygen (HFNO); (4) non-invasive ventilation (NIV); (5) tidal volume setting; (6) PEEP and lung RM; (7) prone positioning; (8) neuromuscular blockade, and (9) extracorporeal life support (ECLS). Each domain was assigned to a group of experts within the panel, and each domain was

coordinated by a 'domain chair'. Panelists were invited to join one or more working groups based on their scientific expertise, geographical representation, and expressed interest. Two additional methodologists and eight patient representatives completed the guideline panel.

Research question selection and literature search

Members of each domain formulated questions according to the Patients or Population- Intervention-Comparison-Outcome (PICO) format. Each PICO question was discussed and agreed with the guideline chairs, methodologists, and the wider panel. For each PICO, a dedicated systematic literature search was performed using the PubMed search engine. For the Definition Domain 1 a systematic review of the literature was not performed and only a discussion was performed by the members on ARDS definition. Phenotypes Domain 2 conducted a systematic review of the literature, summarizing evidence without, however, performing any grading of the evidence. Most studies in this field focused on prognosis in different sub-phenotypes. Few others, investigating the effectiveness of intervention in sub-phenotypes, were meant to generate hypotheses to be verified in future trials more than providing evidence in support of treatments. For both Domains 1 and 2 we preferred a narrative approach over systematic Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) assessments.

Following the literature search, pairs of reviewers from each domain reviewed the titles independently and selected the final list of full-text studies to be included in meta-analysis. The methodologists performed data extraction, synthesis, and risk of bias assessment for individual studies. Details of the meta-analysis procedures are provided in the Supplementary Methods.

Formulation of recommendations and consensus methodology

After reviewing the results of the literature search and meta-analyses, members of each domain formulated statements (recommendations) related to each PICO/narrative question. Recommendations were based on the integration of three main criteria: (1) certainty of evidence (as provided by the methodological assessment); (2) GRADE methodology [8], and (3) expert opinion. Proposed recommendations along with corresponding summaries of evidence were presented and discussed in four online panel-wide meetings which included patient representatives. These meetings were recorded for members who were unable to attend and for accurate reporting of the panel discussion. Following each panel-wide meeting, recommendations were revised based on the feedback received. The finalized recommendations were then

sent to each panel member for anonymous online voting. Strong recommendations were phrased as "recommendations," and weak recommendations were phrased as "suggestions." Approval of a recommendation required at least 80% of the panel to be in agreement. Recommendations with less than 80% agreement were reformulated and re-voted until >80% approval was achieved for all. A detailed description of the methodology is reported in the Supplementary Materials.

Domain 1: ARDS definition

ARDS was first described in 1967 by Ashbaugh and colleagues in 12 patients with new onset hypoxemia refractory to supplemental oxygen, bilateral infiltrates on chest radiograph, and reduced respiratory system compliance. Inflammation, edema, and hyaline membranes were uniformly present in lungs of non-survivors [2]. Subsequently, diagnosis of ARDS evolved from informal pattern recognition to formalized clinical definitions. The Lung Injury Score, proposed in 1988 [14] was supplanted in 1994 by the American-European Consensus Conference (AECC) definition [15], and further updated by an ESICM-sponsored process leading to the 2012 'Berlin Definition' [1, 3]. As part of these 2023 ESICM ARDS Treatment Guidelines, experts from the Definition Domain were charged with highlighting issues that should be addressed in subsequent revisions, based on knowledge accrued in the last decade which may be relevant to the current ARDS definition.

The expert panel discussed expanding the reach of the definition of ARDS and the pros and cons of this expansion. This topic is also important for the application of a definition in resource-poor settings [16]. As an example, the use of HFNO has increased in the past decade, particularly during the COVID-19 pandemic. Proponents suggest that the ARDS definition should be modified to allow patients on HFNO to be eligible for the oxygenation criterion even though they are not being ventilated with PEEP ≥ 5 cmH₂O (as required by the Berlin definition). This approach has face validity in many patients with severe hypoxemia, who are treated with high flows and high FiO₂ on HFNO [17]. Some proponents go further to argue that the requirement for PEEP should be removed regardless of oxygen delivery device used, to allow ARDS to be diagnosed in locations without consistent access to HFNO or ventilation. Opponents argue that this approach may dilute severity of illness among patients labeled as ARDS, as it would also capture patients with a better prognosis [18] or affect comparisons among groups. Similarly, the past decade has also seen increased use of the SpO₂/FiO₂ (S/F) ratio rather than the PaO₂/FiO₂ (P/F) ratio as a measure of the degree of hypoxemia [19, 20]. Proponents argue that the S/F

ratio is less invasive and more readily available, noting its use in current randomized controlled trials (RCTs) [21]. The counterargument, however, is that there are inaccuracies in SpO₂ measurements, particularly among patients with darker skin and those in shock and/or with poor distal perfusion. In addition, many patients are treated to keep their SpO₂ in excess of 97%, resulting in an uninformative S/F ratio [22]. Finally, the inclusion of the chest radiograph criterion remains a question given its moderate-to-poor reliability [23, 24] and limited availability in some settings. A recent RCT failed to demonstrate any improvement in chest X-ray interpretation after a standardized ARDS radiograph training exercise [25]. Other approaches to radiography in ARDS that have been debated over the past decade include eliminating the radiographic criterion altogether; allowing unilateral opacities to meet ARDS criteria, as pediatric critical care has done [26]; requiring computed tomography (CT) scanning to meet the full definition (more accurate but less available even in tertiary centers); and allowing lung ultrasound (more available but operating characteristics less well known and requires training in image acquisition) to meet the definition criteria.

The panel also discussed the minimum timeframe for which patients must continue to meet criteria for ARDS. Experts agree that ARDS is not a transient phenomenon, but instead is a syndrome that takes days or weeks to resolve. The prevalence of rapidly improving ARDS (P/F > 300 or extubated within the first 24 h after diagnosis) in six ARDS Network trials was > 10% and increased over time [27]. If the subjects in a trial have a very low risk of the condition that the intervention is hypothesized to prevent (e.g., VILI), the trial will not verify the value of the intervention. These data prompt the question of how long diagnostic criteria must be present before patients can be diagnosed with ARDS. Experts agreed that some minimum period of stabilization and stability prior to diagnosing ARDS is likely appropriate; however, the length of this period remains uncertain. A long stabilization period would increase specificity but prevent early therapeutic interventions. Since oxygenation can be affected by clinical interventions and ventilator settings, experts have considered whether oxygenation failure in ARDS should be judged using standardized ventilator settings, which could identify higher risk patients but may add further feasibility challenges to trial enrollment [28, 29] and may not confer additional clinical advantages.

The expert panel noted the disconnect between the conceptual model of ARDS—a specific type of inflammation and host response to injury [3]—and the lack of measures of inflammation in ARDS definitions. This disconnect is due to insufficient data on operating

characteristics or poor feasibility of direct measures of pulmonary inflammation or immune response [1]. While some successes have been documented with the application of sub-phenotypes of ARDS (see Domain 2), much work remains to be done to harmonize a clinically feasible definition with the conceptual pathophysiological model of ARDS. At the same time the panel discussed whether predictive validity for mortality is the best measure of an ARDS definition. Diagnostic accuracy in ARDS is challenging without a universal reference standard. Future work in refining the ARDS definition should carefully consider other facets of validity as well as reliability [30]. At the same time, we need new prospective observational studies to better categorize patients with acute non-cardiogenic hypoxemic respiratory failure, including ARDS, across a broad range of characteristics, including imaging and biomarkers, with the goal of developing more personalized treatments. Until such information becomes available, clinicians may at times wish to use the broader umbrella syndrome of acute hypoxemic respiratory failure when deciding to implement certain therapeutic strategies, particularly those that are not directed against specific ARDS mechanisms.

Domain 2: ARDS phenotyping

This group was charged with identifying key issues relating to phenotyping in ARDS, assessing the current literature to address these questions, and identifying the knowledge gaps to be addressed in future research.

A systematic search was conducted to identify studies satisfying the following criteria: (1) identify a sub-phenotype as per our working definition (see below and as described in the supplement); (2) focus on phenotyping in patients with ARDS; (3) human data; (4) include ≥ 100 patients with ARDS; (5) include sub-phenotypes showing heterogeneity of treatment effect or sub-phenotypes showing differences in patient outcome. Twenty-five papers were included in the final analysis [31–55].

Question 2.1: How do we define an ARDS sub-phenotype?

Based on the currently available literature and consensus within the working group, the following definitions were established:

- a. A **phenotype** is a clinically observable set of traits resulting from an interaction of genotype and environmental exposures (i.e., ARDS is a phenotype).
- b. A **subgroup** is a subset of patients within a phenotype, which may be defined using any cut-off in a variable. This cut-off can be arbitrary, and frequently patients fall just on either side of it, resulting in patients switching subgroups (e.g., PaO₂/FiO₂ severity classification of ARDS).

- c. A **sub-phenotype** is a distinct subgroup (of ARDS patients) that can be reliably discriminated from other subgroups based on a set or pattern of observable or measurable properties. Discrimination is typically based on a data-driven assessment of a multi-dimensional description of traits. Subphenotypes should also be reproducible in different populations.
- d. An **endotype** is a sub-phenotype with distinct functional or pathobiological mechanism, which preferably responds differently to a targeted therapy.

Question 2.2: How do we identify or operationalize an ARDS sub-phenotype?

Accurate classification of the sub-phenotype is critical as exemplified by the results of LIVE trial [38]. The trial randomized patients to either standard lung-protective ventilation or a personalized treatment strategy based on radiological sub-phenotype (focal or diffuse pathology on chest radiograph). Overall, there was no benefit to a personalized treatment strategy; however, misclassification of sub-phenotype resulting in misaligned treatment strategies was common, and the results were “positive” when misclassified patients were excluded. Subphenotype classification in prospective studies likely requires: (1) on-site, real-time testing and rapid results, and (2) operator independence.

Question 2.3: What is the evidence for heterogeneity of treatment effect (predictive enrichment) between sub-phenotypes?

Does sub-phenotyping alter patient response to an anti-inflammatory intervention in ARDS?

In a secondary analysis of the HARP-2 trial [35], patients with the hyper-inflammatory sub-phenotype seemed to benefit from simvastatin, although the interaction term for heterogeneity of treatment effect was not statistically significant. In a secondary analysis of the SAILS trial [36], no heterogeneity of treatment effect was identified for the hypo-inflammatory and hyper-inflammatory sub-phenotypes and treatment with rosuvastatin. In a clustering reanalysis of the SAILS trial, 4 sub-phenotypes were described in which one group ($n=66$) defined by high platelets and low creatinine seemed to benefit from rosuvastatin; however, these sub-phenotypes have not been reproduced in other populations [43].

Does sub-phenotyping alter patient response to PEEP interventions in ARDS?

A secondary analysis of the ALVEOLI trial [31] identified heterogeneity of treatment effect between the hypo-inflammatory and hyper-inflammatory sub-phenotypes and PEEP strategy adopted (higher vs lower PEEP/ FiO_2

table). A secondary analysis of the observational LUNG-SAFE study [54] identified a similar pattern, in that patients with the hyper-inflammatory sub-phenotype seemed to benefit from higher PEEP, in contrast to the hypo-inflammatory sub-phenotype. In the LIVE trial described above, a personalized PEEP and prone positioning strategy based on diffuse vs focal radiographic sub-phenotype achieved a reduction in 90-day mortality, when only considering per-protocol treated patients [38]. However, this signal was diluted in the intention to treat analysis due to misclassifications of lung morphology.

Does sub-phenotyping alter patient response to fluid strategies in ARDS?

A secondary analysis of FACTT [33] identified heterogeneity of treatment effect in that patients with the hyper-inflammatory sub-phenotype seemed to benefit from a liberal fluid strategy, in contrast to the hypo-inflammatory sub-phenotype.

Question 2.4: How does sub-phenotyping relate to patient outcome (prognostic enrichment)?

Short term (up to day 90) mortality was found to be different between sub-phenotypes that are based on the following characteristics (see Supplemental Table):

- Systemic inflammatory response gauged by plasma proteins (higher mortality in hyper-inflammatory than in hypo-inflammatory) [31, 34];
- Lung radiographic morphology (higher mortality in non-focal than in focal) [38];
- Recruitability (higher mortality in recruitable than in non-recruitable) [44, 56];
- Clinical features (higher mortality with more organ failure and/or comorbidities and/or acidosis) [47];
- Longitudinal changes in respiratory parameters (higher mortality in upwards trajectory of ventilatory ratio and mechanical power than in steady trajectory) [45]

Question 2.5: What are the research questions related to the use of sub-phenotyping for future trials?

Several research questions remain to be addressed in future studies, particularly regarding: (1) the stability of sub-phenotypes over time, from pre-ARDS through to recovery; (2) whether sub-phenotypes are reproducible across diverse populations; (3) the accuracy and repeatability of a rapid sub-phenotype classification; (4) the pathophysiological pathways that drive the development of sub-phenotypes; (5) the quantification of the attributable mortality of each sub-phenotype; and (6) whether

precision treatment strategy based on sub-phenotypes can improve outcomes after ICU discharge.

Domain 3: High-flow nasal oxygen

Question 3.1: In non-mechanically ventilated patients with acute hypoxemic respiratory failure not due to cardiogenic pulmonary edema or acute exacerbation of chronic obstructive pulmonary disease (COPD), does HFNO compared to conventional oxygen therapy (COT) reduce mortality or intubation?

Background

The effectiveness of COT (i.e., low-flow) delivered via face mask or nasal cannula is limited by low-flow rates (i.e., less than 15 L/min) and lack of humidification of inspired oxygen, which can lead to patient intolerance. HFNO is well tolerated and can deliver heated, humidified oxygen at flow rates up to 60 L/min [57]. At higher flow rates, HFNO can deliver more consistent FiO_2 than COT, decrease anatomical dead space, and provide PEEP up to 3–5 cmH_2O , depending on flow rate and breathing pattern [58]. After the publication of the FLORALI trial in 2015 [59], the use of HFNO in acute hypoxemic respiratory failure increased considerably, which was further augmented during the COVID-19 pandemic.

Summary of the evidence

We evaluated the use of HFNO for patients with AHRF rather than ARDS, given that many patients would not meet the requirement for PEEP of 5 cmH_2O or more using the current Berlin definition. However, most of the patients who progress from HFNO to mechanical ventilation do end up meeting criteria for ARDS. During the COVID-19 pandemic, 93% of patients treated with HFNO who progressed to intubation met criteria for ARDS under the Berlin definition [18]. Given the increasing use of HFNO especially with the COVID-19 pandemic, there is increasing belief that ARDS definition should include those patients with acute hypoxemic respiratory failure on HFNO (see above Domain 1). As such, these PICO and their recommendation should be applicable to ARDS being managed with HFNO. We excluded trials that included patients with acute cardiogenic pulmonary edema, exacerbation of COPD, acute hypercapnic respiratory failure, or use of HFNO post-extubation. We identified seven RCTs that formed the basis of our recommendations [59–65]. The study by Bouadma and collaborators [65], however, was included only in a sensitivity analysis because of its design and uncertainties in the interpretation of its findings (see Supplementary Materials).

Among 2769 patients included in six trials with a combined 28- or 30-days mortality of 20.5%, there was no statistically significant difference in mortality between HFNO compared to COT (relative risk (RR) 0.95, 95% confidence interval (95% CI) 0.82–1.09). Further, there was no evidence for differences in treatment effect in the subgroups based on immunocompromised or COVID-19 status.

The pooled rate of intubation at 28–30 days among the six analyzed trials was 43%. Meta-analysis identified a significant beneficial effect of HFNO compared to COT in preventing intubation (RR 0.89, 95% CI 0.81–0.97). Individual study estimates of treatment effect for risk of intubation were consistent across most included trials, except for one trial that contributed only 1.6% of weight to the pooled estimate [64]. We did not identify significant differences in intubation rate between HFNO and COT in subgroups of patients based upon immunocompromised state or COVID-19 infection.

Recommendation 3.1

We **recommend** that non-mechanically ventilated patients with AHRF not due to cardiogenic pulmonary edema or acute exacerbation of COPD receive HFNO as compared to conventional oxygen therapy to reduce the risk of intubation
Strong recommendation; moderate level of evidence in favor

We are **unable to make a recommendation** for or against the use of HFNO over conventional oxygen therapy to reduce mortality
No recommendation; high level of evidence of no effect

This recommendation applies also to AHRF from COVID-19
Strong recommendation; low level of evidence in favor for intubation and no recommendation; moderate level of evidence of no effect for mortality, for indirectness.

Expert opinion on clinical application

HFNO was found to be superior to COT in reducing the risk of intubation but not in reducing mortality among patients with AHRF [59–65]. Mechanical ventilation is resource-intensive and is associated with higher need for sedation and immobility, which have been associated with higher rates of complications such as delirium, nosocomial infection, mortality, worse long-term morbidity, including physical and cognitive complications. In addition, input from the patient representatives indicated that most patients would value avoiding intubation if possible. Thus, there may be benefits from preventing intubation, even in the absence of a significant improvement in mortality. HFNO is generally well tolerated by patients and is associated with similar or lower incidence of adverse event rates compared to COT. Therefore, we advocate the use of HFNO compared to COT for patients with AHRF regardless of immunocompromised or COVID-19 status.

Unresolved questions and research gaps

Long-term functional outcome data are missing from randomized controlled trials investigating the use of HFNO in acute respiratory failure. As such, it is unknown whether prevention of intubation can decrease symptoms and long-term functional impairment reported by AHRF survivors. Additionally, it is not clear how long a trial of HFNO should last or whether indices such as respiratory rate - oxygenation (ROX) index or other measures should be utilized to indicate failure of HFNO and need for intubation [66]. Indeed, in some of the trials, patients who failed HFNO had a higher mortality than patients treated with conventional oxygen [59, 67]. It is not clear whether this was due to some delay in intubation or only reflected more severe disease. A future large trial comparing HFNO to COT powered for mortality may be difficult to conduct and interpret due to cross-overs, given the increased adoption of HFNO use after the COVID-19 pandemic. Future clinical trials should examine how HFNO can best be delivered to maximize benefit would guide clinicians on how to use and discontinue HFNO in AHRF. In addition, long-term outcomes (e.g. cognitive, functional, and quality of life) need to be incorporated to determine the long-term impact of HFNO.

Question 3.2: In non-mechanically ventilated patients with AHRF not due to cardiogenic pulmonary edema or acute exacerbation of COPD, does HFNO compared to non-invasive ventilation reduce mortality or intubation?

Background

Non-invasive ventilation improves outcomes and has been recommended for patients with acute hypercapnic respiratory failure from acute exacerbations of COPD or patients with cardiogenic pulmonary edema [68]. In most prior guidelines, no specific recommendation has been made for the use of NIV for patients with AHRF from other etiologies due to insufficient evidence. Additionally, concerns have been raised about tolerance of NIV, ability to clear secretions, worsening lung injury from large tidal volumes on inspiratory pressure support (especially given the high inspiratory demand seen in AHRF), and possible harm resulting from delaying intubation.

Early in the COVID-19 pandemic, NIV was frequently used (up to 47% of ICU patients in Wuhan) [69]. Initial clinical practice guidelines from the National Institute of Health and Surviving Sepsis Campaign provided a weak recommendation in favor of HFNO compared to NIV for the treatment of COVID-19 pneumonia, and for use of NIV if HFNO was not available or had failed [70, 71]. This recommendation was based upon data extrapolated from non-COVID-19 related AHRF, and studies in patients with Middle East Respiratory Syndrome (MERS)

that showed a high rate of intolerance and failure of NIV, with high mortality among those who failed NIV [59, 72]. In addition, concerns existed regarding the potential for increased aerosol transmission of the virus with NIV [73].

Summary of the evidence

We focused on patients with AHRF and excluded trials that enrolled patients with acute cardiogenic pulmonary edema, exacerbation of COPD, acute hypercapnic respiratory failure, or mechanically ventilated patients who used NIV after extubation or to facilitate extubation. We identified four RCTs that reported mortality [59, 74–76], including two RCTs that enrolled COVID-19 patients. Among other trials, we excluded a three-arm trial where the intervention in the common control arm was COT and there was no direct randomization of patients to HFNO vs NIV [60].

Of the two RCTs enrolling non-COVID-19 patients, one included immunocompromised patients [76], the other non-immunocompromised patients [59]. We did not include one trial in the pooled analysis for intubation as only 7-day intubation outcome was reported [74]. Meta-analysis did not identify a significant difference comparing HFNO to NIV for either mortality (RR 0.75 95% CI 0.51–1.11) or intubation (RR 1.09 95% CI 0.71–1.68).

Meta-analysis did not identify significant differences in mortality in HFNO vs NIV within subgroups of immunocompromised or COVID-19 patients. Regarding intubation, in the trial by Grieco et al. HFNO was associated with a significant increase in the rate of intubation at 28 days compared to NIV in patients with COVID-19 (RR 1.72 95% CI 1.06–2.79) [75]. However, the trial by Nair et al. (not included in the primary meta-analysis because it reported intubation rate only up to day 7) [74] showed a statistically significant effect in the opposite direction (a 19% absolute risk reduction in the HFNO arm).

Recommendation 3.2

We are **unable to make a recommendation** for or against the use of HFNO compared to continuous positive airway pressure (CPAP)/NIV to reduce intubation or mortality in the treatment of unselected patients with acute hypoxemic respiratory failure not due to cardiogenic pulmonary edema or acute exacerbation of COPD.
No recommendation; moderate level of evidence for mortality, low level of evidence for intubation, not in favor nor against.

We **suggest** that CPAP/NIV can be considered instead of HFNO for the treatment of AHRF due to COVID-19 to reduce the risk of intubation (*weak recommendation, high level of evidence*), but **no recommendation** can be made for whether CPAP/NIV can decrease mortality compared to HFNO in COVID-19.
No recommendation; high level of evidence of no effect.

Expert opinion on clinical application

The panel suggest that clinicians managing AHRF patients with CPAP/NIV should have appropriate experience and expertise, and patients should have appropriate monitoring (e.g. clinical signs of respiratory distress, breathing pattern—tidal volume (Vt) and respiratory rate—and inspiratory effort) to avert P-SILL. Additionally, clinicians should consider how well individual patients may tolerate NIV and the risk of adverse events.

Unresolved questions and research gaps

There is an urgent need for RCTs that compare HFNO to NIV/CPAP for patients with AHRF using important endpoints such as mortality, intubation, and total duration of mechanical ventilation. Long-term patient follow-up and cognitive and function outcomes assessments would enable determination of whether observed differences in short-term outcomes (e.g., intubation) are associated with long-term impairment in survivors.

Domain 4: CPAP/NIV

Question 4.1: In non-mechanically ventilated patients with AHRF not due to cardiogenic pulmonary edema, obesity hypoventilation or acute exacerbation of COPD, does CPAP/NIV, as compared to conventional oxygen therapy reduce mortality or intubation?

Background

While hypoxemia and ventilatory dysfunction in patients with AHRF can be addressed with different non-invasive modalities, with differential effects on end-expiratory alveolar pressure and/or inspiratory effort [77], a concern regarding the use of CPAP/NIV is the potential delay in intubation, which might lead to worse outcomes, including increased mortality. Moreover, high transpulmonary pressures can be observed during NIV (due to either high level of support, strong inspiratory effort, or both) potentially leading to P-SILL, analogous to the ventilator-induced lung injury described during invasive controlled ventilation [11]. The specific physiological effects need to be considered when selecting non-invasive strategies for AHRF. Of note, patients with AHRF not receiving positive pressure cannot be classified as ARDS patients using the current Berlin definition as they do not receive at least 5 cmH₂O of PEEP. As previously mentioned, the ARDS definition may need include these patients who have the same disease from a pathophysiological point of view.

Summary of the evidence

We included ten randomized controlled trials which enrolled patients with non-COVID-19 and COVID-19 AHRF, immunocompetent and immunocompromised [59, 60, 78–85]. Six of these studies investigated the effect of NIV compared to COT [59, 81–85], while four compared CPAP vs. COT [60, 78–80]. One trial with CPAP performed in COVID-19 patients randomized patients either to CPAP or to HFNO vs. COT [60]. For the main analysis, we combined all ten studies, without any subgroup distinctions. We hypothesized that NIV and CPAP were similarly effective; hence, we included studies adopting either intervention for purposes of the meta-analysis. When the intervention was NIV, the type of ventilator (ICU, dedicated to NIV or home ventilator) and the type of the circuit used (single or double limb circuit) were assumed not to affect outcomes.

We performed a primary meta-analysis focused on five RCTs with low risk of bias and individual moderate to high quality [59, 60, 78, 81, 82]. However, the risk of bias increased when the outcome was intubation, because of lack of blinding. This meta-analysis did not identify a significant effect of CPAP/NIV compared to COT on intubation (RR 0.89, 95% CI 0.77–1.03) or hospital mortality (RR 0.89, 95% CI 0.75–1.05). A secondary analysis was performed including all studies independently from the risk of bias assessment and quality (see Supplementary Materials). This secondary analysis showed a protective effect in terms of intubation rate and mortality. However, according to our predefined statistical planned, when the results of the primary and secondary analysis were inconsistent, the primary analysis prevailed.

Only one study was available in COVID-19 patients [60] which reported a lower intubation rate with CPAP compared to conventional oxygen therapy but no difference in mortality.

Recommendation 4.1

We are **unable to make a recommendation** for or against the use of CPAP/NIV compared to conventional oxygen therapy for the treatment of AHRF (not related to cardiogenic pulmonary edema or acute exacerbation of COPD) to reduce mortality or to prevent intubation.

No recommendation; high level of evidence for mortality, moderate level of evidence for intubation.

We **suggest** the use of CPAP over conventional oxygen therapy to reduce the risk of intubation in patients with acute hypoxemic respiratory failure due to COVID-19.

Weak recommendation; low level of evidence in favor.

In this population, we are **unable to make a recommendation** for or against the use of CPAP over conventional oxygen therapy to reduce mortality.

No recommendation; moderate level of evidence of no effect.

Unresolved questions and research gaps

Analysis of available scientific evidence does not allow conclusions regarding the use of CPAP/NIV over COT to prevent intubation or to reduce mortality in patients with non-COVID-19 AHRF. In the panel's view, it is advisable that future research should better characterize patients at inclusion to identify optimal indications for CPAP/NIV in the management of acute hypoxemic respiratory failure. Given recent physiological evidence [86], the panel suggests focusing on the potential role of high vs. low respiratory drive in determining suitability for NIV and likelihood of success.

Question 4.2: In patients being treated with CPAP/NIV for AHRF, does the use of a helmet interface as compared to face mask reduce intubation or mortality?

Background

NIV in the acute care setting is usually applied via a face mask interface, which can be poorly tolerated resulting in a risk for NIV failure. Helmet is an alternative interface to deliver NIV. Several studies reported that NIV via helmet was well tolerated and reduced skin pressure injuries [87, 88]. Managing patient-ventilator synchrony can, however, be challenging during helmet NIV [89, 90], and specific expertise is needed to optimize ventilatory settings.

Summary of the evidence

Only one small, single-center RCT was identified [91]. Eighty-three patients with hypoxemic respiratory failure requiring NIV were randomized to either face mask or helmet interface. There was a 22.3% mortality reduction (95% CI -41.1 to -1) and a 43.4% reduction of intubation rate (95% CI -59.5 to -22.5) with the helmet. A second publication was a follow-up study of the same dataset, focused on functional outcomes [92]. Although the study had only moderate limitations, the panel had concerns given (a) small sample size and early termination for efficacy might cause an overestimation of the treatment effect, and (b) single-center trial might have issues related to external validity. The panel considered this study as hypothesis-generating rather than conclusive evidence of helmet superiority.

Recommendation 4.2

We are **unable to make a recommendation** for or against the use of helmet interface for CPAP/NIV as compared to face mask to prevent intubation or reduce mortality in patients with acute hypoxemic respiratory failure.
No recommendation; very low level of evidence in favor.

Unresolved questions and research gaps

Additional studies comparing helmet and facemask interface are needed before being able to recommend one of these two interfaces compared to the other.

Question 4.3: In patients with AHRF, does NIV as compared to CPAP reduce mortality or intubation?

Background

NIV can generate high transpulmonary pressure when respiratory drive and effort are high. The application of additional positive pressure assistance during inspiration could lead to higher transpulmonary pressures and total stress applied to the lung, particularly when respiratory drive is high. CPAP may thus benefit patients with acute hypoxemic respiratory failure, possibly lowering the swings in transpulmonary pressure compared to NIV.

Summary of the evidence

We found no randomized study that addressed this PICO question and were thus unable to make a recommendation for or against the use of NIV compared to CPAP for the treatment of ARDS.

Recommendation 4.3

We are **unable to make a recommendation** for or against the use of NIV compared to CPAP for the treatment of AHRF.
No recommendation; no evidence.

Expert opinion on clinical application

Conceptually, the use of CPAP in case of acute hypoxemic respiratory failure is of interest but there are no data available comparing this strategy with NIV.

Unresolved questions and research gaps

Randomized studies are needed to assess whether NIV as compared to CPAP reduces the risk of intubation or decreases mortality.

Domain 5: Low tidal volume ventilation

Question 5.1: In adult patients ARDS and COVID-19-related ARDS, does low tidal volume ventilation alone compared with more traditional approaches to ventilation decrease mortality?

Background

In the early 1960s, researchers and clinicians showed that mechanical ventilation with small Vt caused gradual loss of lung volume with hypoxemia due to right-to-left shunting through regions with poor ventilation. Consequently, use of large tidal volumes of 12–15 mL/kg body

weight was recommended [93]. Recognition of a number of physiological concepts changed this approach and led to the current era of lung-protective ventilation using small Vt: (i) hypercapnia and respiratory acidosis are well tolerated if the patient is well oxygenated, (ii) mechanical ventilation that allows for derecruitment and recruitment of lung units and/or over-distension of lung units associated with high transpulmonary pressures can worsen existing lung injury or may lead to de novo lung injury, and (iii) the effective pulmonary gas volume in patients with ARDS is decreased (baby lung) and thus ventilation with even ‘normal Vt’ can lead to over-distension and VILI. A corollary of this latter concept is that in patients with severe ARDS, regional lung over-distension can occur even if these patients are ventilated with small tidal volumes [94]. The recognition of VILI led to the concept of “protective ventilation” as many of the pathophysiological consequences of VILI mimic those of ARDS. This development heralded current use of low Vt ventilation strategies with appropriate levels of PEEP to limit lung distention and atelectrauma.

Use of ventilation strategies with low Vt has been shown in animal and human studies to decrease VILI. In the clinical setting, low Vt ventilation is implemented by delivering tidal volumes in the range of 4–8 mL/kg predicted body weight (PBW), without aiming for optimal gas exchange, but accepting gas exchange within safety parameters. Traditionally used approaches to invasive mechanical ventilation have not prioritized limiting VILI but have focused on normalizing arterial blood gases.

Summary of the evidence

We identified seven RCTs, that met our inclusion criteria [28, 95–100], and constituted the basis of these recommendations.

ARDS was variably defined in the included trials. Whereas one trial included patients with a Lung Injury Score (LIS) ≥ 2.5 and a risk factor for ARDS [96], another trial included patients with a LIS > 2.5 for < 72 h, bilateral

infiltrates, and at least one organ system failure [95]. Other trials included patients based on a PaO₂/FiO₂ ratio ≤ 150 mmHg with infiltrates in at least 3 out of 4 quadrants on chest radiograph and a risk factor for ARDS [100], PaO₂/FiO₂ ≤ 200 mmHg with bilateral infiltrates [98], PaO₂/FiO₂ ≤ 200 mmHg on PEEP of 5 cmH₂O with Vt 5 mL/kg for 24 h that persisted for at least 24 h [28], PaO₂/FiO₂ < 250 mmHg on PEEP of 5 cmH₂O with a risk factor for ARDS [97], or PaO₂/FiO₂ < 300 mmHg with bilateral infiltrates [99].

The target Vt and airway pressure limits in the intervention and control arms of the included trials were variably defined (see Table 1). Importantly, five trials were stopped early [28, 95, 96, 98, 99]. No randomized trials specifically compared these ventilator approaches in patients with COVID-19.

We performed a primary analysis based on studies with moderate to high quality of evidence according to the GRADE method, and a secondary analysis including all the studies.

The primary analysis concerning mortality included three trials [95, 97, 99] and found no evidence of difference in mortality, comparing low Vt strategies to high Vt strategies (RR 0.96 95% CI 0.72–1.28, *p* value for effect 0.768). The analysis of heterogeneity using the *I*² measure was inconclusive with an estimate of 61% but substantial imprecision (95% CI ranging between 0 and 89%, Cochran’s *Q* test *p* value = 0.08).

The secondary analysis was consistent with the primary analysis with RR 0.82 (95% CI 0.66–1.02) *p* value for effect 0.069. The analysis of heterogeneity bore inconclusive results because of its imprecision, with *I*² = 47%, 95% CI ranging between 0 and 78%, and the Cochran’s *Q* test *p* value = 0.08).

Not statistically differences were found investigating ventilator-free days and barotrauma in those trials that provided this information (Supplementary Materials).

Although the mortality summary estimate did not achieve statistical significance, in developing our

Table 1 Summary of studies comparing low vs high tidal volume ventilation

	Vt (ml/kg)		Paw Limit (cmH ₂ O)		Notes
	Interventional Arm	Control Arm	Interventional Arm	Control Arm	
Villar et al. [28]	5–8 PBW	9–11 PBW	PIP 35–40	PIP < 35 –40	
Brochard et al. [95]	6–10 ABW	10–15 ABW	Pplat ≤ 25 –30	PIP ≤ 60	
Amato et al. [96]	< 6 ABW	12 ABW	PIP < 40 and $\Delta P < 20$	–	RM allowed – Explicit sedation protocol
Stewart et al. [97]	≤ 8 IBW	10–15 IBW	PIP ≤ 30	PIP ≤ 50	
Brower et al. [98]	5–8 PBW	10–12 PBW	Pplat < 30	Pplat < 45 –55	
ARDS Net [99]	4–8 PBW	12 PBW	Pplat ≤ 30	Pplat ≤ 50	PP allowed – Explicit weaning protocol
Orme et al. [100]	4–8 PBW	10–15 PBW	Pplat < 40	Pplat < 70	Explicit sedation and weaning protocol

Vt Tidal Volume, Paw Airway Pressure, PBW Predicted Body Weight, ABW Adjusted Body Weight, PIP Peak airway pressure, Pplat Plateau airway pressure, ΔP Driving Pressure, RM Recruitment Manoeuvre, PP Prone Positioning

recommendation statements, we considered the extremely strong physiologic rationale underpinning the use of low Vt ventilation based on animal and human studies. We downgraded the evidence for one trial that was not published in full [100]. We also downgraded the evidence for two trials that used an explicit protocol to keep PEEP in the intervention arm 2 cmH₂O above the lower inflection point of the pressure–volume curve [28, 96] or at 13 cmH₂O in one trial [28] and permitted the use of RM [96]. Both trials were small, reported few death events, and stopped early for benefit [28, 96]. In developing this recommendation, we also considered that no new trials have published in this area since 2006, tidal volumes were variably calculated using adjusted body weight (ABW), ideal body weight (IBW) and predicted body weight (PBW), and that different gradients were achieved between study arms among the included trials. We also acknowledged that low Vt ventilation strategies may require increased sedation and/or paralysis; these effects, along with those related to permissive hypercapnia, were not explicitly evaluated.

In the absence of evidence directly related to use of the alternative approaches in COVID-19 patients, we downgraded the recommendation due to indirectness of evidence. However, there is no reason to expect that the underlying physiological rationale which supports the use of low tidal volumes should be different for COVID-19 vs. non-COVID-19 ARDS. In developing this recommendation, we considered the balance between patients' values and preferences, desirable and undesirable effects, resource use, acceptability to involved stakeholders, feasibility, and equity.

Recommendation 5.1

We **recommend** the use of low tidal volume ventilation strategies (i.e., 4–8 mL/kg PBW), compared to larger tidal volumes (traditionally used to normalize blood gases), to reduce mortality in patients with ARDS not due to COVID-19.

Strong recommendation based on expert opinion despite lack of statistical significance; high level of evidence.

This recommendation applies also to ARDS from COVID-19.
Strong recommendation; moderate level of evidence for indirectness.

Expert opinion on clinical application

When considering the RCTs, it is important to underscore that Vt was reduced when airway pressure limits (as specified by protocols for the intervention and control arms of each individual trial) were reached. It is also very important to highlight that the Vt used in the control arms can no longer be considered as “conventional”, and that no further trials have been conducted in this area for well over a decade. Moreover, it is unlikely that other RCTs will be conducted in the future given a general lack of equipoise in the field regarding this question.

At present, the current approach to support patients with ARDS includes limiting Vt to 4–8 mL/kg PBW and maintaining plateau airway pressure (Pplat) < 30 cmH₂O. Although some investigators use the terms IBW and PBW interchangeably, Vt should be measured and adjusted using PBW.

Similarly, it is unlikely that an RCT of low Vt ventilation in COVID-19 related ARDS will be conducted. Although patients with COVID-19 were not included in the RCTs which form the basis of these recommendations, there is biological plausibility for the use of low Vt ventilation in these patients since the underlying respiratory system mechanics are similar [101], and the physiologic mechanisms that underpin the use of low Vt ventilation in non-COVID-19 ARDS are similar. However, the rate of serious and prolonged multidimensional disability, particularly in patients with COVID-19, may be important and may be further exacerbated by the need for prolonged deep sedation with or without paralysis.

Unresolved questions and research gaps

Future studies are needed to evaluate the merits of additional lung-protective strategies (e.g., limited driving pressure or plateau pressure, elastance normalized to PBW, appropriate levels of PEEP) and personalized ventilator targets, particularly the trade-off between tidal volume and respiratory rate to control the overall intensity of mechanical ventilation [102] balanced by the risks of very low tidal volumes (e.g., sedation, dyssynchrony etc.) in patients with lower lung elastance. Long-term multidimensional outcomes for patients and families should be included, and the views of patients and caregivers should be central to determining future research questions and outcomes.

The key research questions to be addressed in future trials include investigation of: (1) the optimal manner to assess whether a given ventilator strategy is likely to worsen VILI, (2) the manner in which we determine optimal Vt (e.g., based on PBW, on driving pressure, or an alternative approach), (3) personalized lung-protective ventilatory strategies based on the physiology of individual patients, and (4) other approaches to remove PaCO₂ if the current ventilator strategy is highly likely to worsen VILI.

Domain 6: PEEP and recruitment maneuvers

Question 6.1: In patients with ARDS undergoing invasive mechanical ventilation, does *routine* PEEP titration using a higher PEEP/FiO₂ strategy compared to a lower PEEP/FiO₂ strategy reduce mortality?

Background

In patients with ARDS, surfactant dysfunction, effects of gravity on the edematous lung, and heterogeneous injury

predispose to regional lung derecruitment with alveolar collapse and small airways closure [103]. The resulting mechanical heterogeneity of the lung, with regional differences in alveolar compliance and distension, is thought to be an important driver of ventilation-induced lung injury in ARDS [104, 105]. Positive end-expiratory pressure may offset these forces, promoting lung recruitment and attenuating mechanical heterogeneity. PEEP is also routinely applied to facilitate adequate oxygenation. Yet, excessive PEEP can exacerbate over-distension, potentially predisposing to hyperinflation lung injury and hemodynamic compromise. The following analyses evaluate randomized clinical trials for effects of various PEEP strategies on mortality, ventilator-free days, barotrauma, and hemodynamic compromise.

Summary of the evidence

Three multi-center randomized clinical trials were identified that compared a higher versus lower PEEP/FiO₂ strategy: ALVEOLI [106], LOVS [107], and EXPRESS [108]. ALVEOLI ($n=549$) and LOVS ($n=983$) each evaluated higher versus lower PEEP/FiO₂ titration tables, which specified allowable combinations of PEEP and FiO₂ with instructions to target the lowest allowed combination. The EXPRESS trial ($n=767$) compared PEEP titrated to achieve a plateau pressure of 28–30 cmH₂O (herein identified as the higher-PEEP strategy) versus a minimal distension strategy with PEEP adjusted between 5 and 9 cmH₂O (herein identified as the lower PEEP strategy). Four endpoints were considered in our evidence synthesis: efficacy endpoints (mortality and ventilator-free days), and safety endpoints (barotrauma and hemodynamic instability).

The primary outcome for all three trials was some formulation of mortality, which was not significantly different in any of the three trials nor in the meta-analysis (pooled risk ratio for hospital mortality 0.93; 95% CI 0.83–1.04). Ventilator-free days (VFD) was not pooled since it was only being reported in two trials, one using medians and the other mean values. VFD was not significantly different in ALVEOLI. Though VFD was not reported in LOVS, duration of mechanical ventilation among survivors was not significantly different. In EXPRESS, the higher-PEEP group had significantly more VFD than the lower PEEP group. Incidence of barotrauma did not differ significantly in any of the three trials nor in the meta-analysis (pooled RR 1.17; 95% CI 0.90–1.52). Hemodynamic instability was not meta-analyzed due to reporting differences among trials. In ALVEOLI, hemodynamic instability was not reported directly in the primary publication. In LOVS, hemodynamics was reported as days of vasopressor use and number of vasopressors per day in use, and were comparable between groups. In EXPRESS, significantly more patients in the

higher-PEEP group required fluid loading during the first 72 h (75.3 vs. 66.8%; $p=0.01$), but there was no significant difference in patients requiring vasopressor therapy.

Recommendation 6.1

We are **unable to make a recommendation** for or against routine PEEP titration with a higher PEEP/FiO₂ strategy versus a lower PEEP/FiO₂ strategy to reduce mortality in patients with ARDS. *No recommendation; high level of evidence of no effect.*

This statement applies also to ARDS from COVID-19. *No recommendation; moderate level of evidence of no effect for indirectness.*

Question 6.2: In patients with ARDS undergoing invasive mechanical ventilation, does routine PEEP titration based principally on respiratory mechanics compared to PEEP titration based principally on a standardized PEEP/FiO₂ table reduce mortality?

Summary of the evidence

Four randomized clinical trials were identified that compared a mechanics-based PEEP strategy to a standardized PEEP/FiO₂ table: EPVent [109], EPVent-2 [110], Pintado et al. [111], and ART [112]. EPVent ($n=61$) was a single-center trial that compared PEEP titrated with an end-expiratory transpulmonary pressure (PL)/FiO₂ table versus a low PEEP/FiO₂ table. EPVent-2 ($n=200$) was a multi-center trial that compared PEEP titrated with a PL/FiO₂ table versus a high PEEP/FiO₂ table. In EPVent and EPVent-2, transpulmonary pressure was calculated as airway minus pleural pressure, the latter estimated with esophageal manometry. Pintado et al. ($n=70$) was a single-center trial that compared PEEP titrated to achieve highest respiratory compliance (i.e., lowest driving pressure, defined as plateau pressure minus total PEEP) versus a low PEEP/FiO₂ table. ART was a multi-center trial ($n=1010$) that compared PEEP titrated to 2 cmH₂O above that which achieved highest respiratory compliance versus a low PEEP/FiO₂ table. Notably, in ART, patients assigned to the compliance-guided PEEP strategy also underwent a prolonged high-pressure recruitment maneuver of several minutes duration prior to selecting PEEP, which was thought to directly cause cardiac arrest in at least three trial participants.

Mortality was not statistically significant in the EPVent, EPVent-2, or Pintado et al. trials. However, in ART, mortality was significantly higher in the mechanics-based group (RR 1.12; 95% CI 1.00–1.26). The pooled mortality in the meta-analysis was not significant with a mechanics-based PEEP strategy versus a PEEP/FiO₂ table (pooled RR 0.85; 95% CI 0.57–1.29).

Barotrauma did not differ between groups in EPVent, EPVent-2, or Pintado et al. However, in ART, the incidence of barotrauma was significantly greater in the mechanics-based PEEP group (RR 3.56; 95% CI 1.64–7.73). In pooled analysis, there was no significant difference in barotrauma incidence (pooled RR 1.76, 95% CI 0.76–4.06).

The results of ventilator-free days analyses were inconclusive. The ART trial showed a statistically significant one-day reduction of VFDs, a finding that was not confirmed by EPVent-2. Our secondary analysis based on the meta-analysis of those studies using medians also provided a statistically non-significant result (Supplementary Materials).

Hemodynamic instability was not meta-analyzed due to reporting differences among trials. EPVent did not report measures of hemodynamic instability. In EPVent2, shock-free days did not differ significantly between groups. In the trial by Pintado et al., the mechanics-based PEEP group had significantly less hemodynamic instability (hemodynamic failure-free days, defined as cardiovascular sequential organ failure assessment score > 2). By contrast, in ART, the mechanics-based PEEP group had significantly more hemodynamic instability (need to initiate or increase vasopressor or mean arterial pressure < 65 mmHg in the first hour).

Recommendation 6.2

We are **unable to make a recommendation** for or against PEEP titration guided principally by respiratory mechanics, compared to PEEP titration based principally on PEEP/FiO₂ strategy, to reduce mortality in patients with ARDS.

No recommendation; high level of evidence of no effect.

This statement applies also to ARDS from COVID-19.

No recommendation; moderate level of evidence for indirectness.

Expert opinion on clinical application: PEEP titration in ARDS

PEEP titration is a potentially important determinant of patient outcomes in ARDS and one for which the optimal strategy remains to be defined. Trials included in the meta-analysis demonstrated both potential for benefit and harm from studied PEEP titration protocols. While some level of PEEP is thought necessary to prevent progressive derecruitment, what constitutes ideal PEEP to attenuate lung injury and avoid hyperinflation is unknown. In patients with more severe hypoxemia, previous meta-analyses showed potential survival benefit in favor of higher-PEEP levels [113, 114]. However, excessive PEEP unequivocally can cause barotrauma and hemodynamic instability (prompting additional fluid resuscitation or vasopressor escalation, with untoward

consequences), though what constitutes “excessive PEEP” is not well defined.

Unresolved questions and research gaps: PEEP titration in ARDS

Between-patient differences in severity and pattern of lung injury, lung and chest wall mechanics, tidal volume, positioning, spontaneous breathing effort, cardiac function, intra-vascular volume, and vascular tone all may contribute to variable effects of PEEP. The individual effect of different levels of PEEP may require studies incorporating a recruitability test pre-randomization to test the effect of PEEP in patients with higher potential for lung recruitment. Also, the hemodynamic cost of higher PEEP including the effects on the total volume of fluids administered needs further data. Similarly, the use of esophageal pressure-guided PEEP and distending pressure will require further studies to balance dependent lung recruitment while limiting overall lung distension and stress and strain of the non-dependent lung. In the absence of these data how best to individualize PEEP in clinical practice remains unclear. Finally, the interactions between radiological distribution of opacities, recruitability, positioning and PEEP levels need to be elucidated.

Question 6.3: In patients with ARDS undergoing invasive mechanical ventilation, does use of prolonged high-pressure recruitment maneuvers, compared to not using prolonged high-pressure RMs, reduce mortality?

Background

Ventilator recruitment maneuvers, broadly defined, consist of a temporary increase in airway and transpulmonary pressure, to values higher than encountered during tidal ventilation, for the goal of promoting re-aeration of previously gasless regions, i.e., lung recruitment [115]. Because the pressure required to open collapsed lung units generally exceeds closing pressure [116–118], the transient pressure increase with an RM theoretically could be sufficient to achieve a durable increase in end-expiratory lung volume after the RM is completed. The resulting increase in end-expiratory lung volume with an RM may improve gas exchange, homogenize alveolar distension, and decrease lung stress and strain [105, 119], though occurrence and durability of these effects are variable [115, 119]. As a high-pressure maneuver, RMs also may risk complications related to over-distension, including barotrauma, reduced venous return, increase in pulmonary vascular resistance, right ventricular failure—leading to hemodynamic collapse. Several potential strategies for performing RMs have been described and differ by duration, pressure target(s), frequency, and ventilator maneuver.

Pathophysiological considerations

The pre-requisite for RMs to be effective is the prevalence of collapsed but otherwise functional pulmonary units, i.e. units which are “empty” and gasless due to external compressive forces and/or complete gas reabsorption. Recruitment, however, is an umbrella term that includes several realities with different conceptual definitions. Indeed, recruitment has been defined as:

1. Re-aeration of previously gasless pulmonary units (CT scan) [120];
2. Re-aeration of previously gasless and poorly aerated pulmonary units (CT scan) [121];
3. Difference between expected respiratory compliance vs measured after PEEP increased (double pressure–volume, P–V curves) [122];
4. Modifications of different lung ultrasound score (LUS) entities, assessed by a semi-quantitative score [123].

These methods provide largely different recruitment estimates, particularly the imaging-based methods vs. the P–V curve-based method [124]. However, whatever method is used, the common purpose is to achieve open stability of collapsed alveolar units and quantify the resulting anatomical or functional change. PEEP just maintains what has already been opened by a higher opening pressure. The pressures necessary to open the pulmonary units have been reported in few studies in humans with ARDS [116, 117]. The reported opening pressures, as measured by CT scans, have median values between 20 and 30 cmH₂O and range from 10 to 50 cmH₂O, showing a near Gaussian distribution. However, only a small percentage of pulmonary units (about 10%) open pressures greater than 45 cmH₂O—suggesting limited functional gains in applying pressures above 45 cmH₂O; such high pressures have a hemodynamic price, often paid with large amounts of fluids and with additional cardiovascular stress, morbidity and mortality. The median of closing pressures is around 10 cmH₂O, but collapse of pulmonary units is already observed at pressures that may exceed 20–25 cmH₂O [125, 126].

These observations lead to the following considerations:

1. If the plateau pressure is maintained at 30 cmH₂O, a portion of the pulmonary units opened during recruitment maneuvers at pressures higher than the plateau pressure will unavoidably collapse again. This process is associated with deterioration in gas exchange and possible atelectrauma until their collapse is fully established. To keep the lung fully open after recruitment at a pressure of 45 cmH₂O, PEEP

values greater than 20–25 cmH₂O are necessary [125, 126].

2. During ultra-protective lung ventilation, a Pplat lower than 30 cmH₂O may encourage progressive lung collapse of the units previously opened by RM performed at pressures greater than 30 cmH₂O.
3. In physiological studies, intermittent ‘sighs’ have been shown to counteract the lung collapse occurring in lung-protective strategies [127].

All the above considerations and numeric indications refer to the whole respiratory system. A more exact approach would require the partitioning of lung mechanics (i.e., quantify the relative contribution of the chest wall), as the same recruitment airway pressure may have a different effect, depending on the chest wall elastance.

The analysis evaluated randomized clinical trials that assigned patients to undergo an RM versus no RM for their effects on mortality, ventilator-free days, barotrauma, and hemodynamic instability.

Summary of the evidence

A prolonged high-pressure RM was defined as a strategy intended to facilitate lung recruitment in which airway pressure of ≥ 35 cmH₂O was maintained for at least one minute. Five trials were included which evaluated the effects of a prolonged high-pressure RM, versus no such maneuver, on hospital mortality. Hodgson et al. in 2011 ($n=20$) [128] and in 2019 (PHARLAP trial, $n=115$) [129] evaluated a prolonged “staircase” RM in which PEEP was set to 20, 30, and then 40 cmH₂O for 2 min each, followed by a decremental PEEP titration to 15 cmH₂O or until desaturation; the comparison group received no RM and a low PEEP/FiO₂ strategy. Kung et al. ($n=120$) [130] evaluated an RM in which PEEP was set to 35 cmH₂O for two minutes followed by decremental PEEP titration until maximum compliance was identified; the comparison group received no RM and a low PEEP/FiO₂ strategy. Chung et al. ($n=24$) [131] evaluated an RM consisting of raising PEEP from 10 to 40 cmH₂O in increments of 5 cmH₂O, with 40 seconds at each recruitment, followed by a decremental PEEP titration; the comparison group received no RM. The ART trial ($n=1010$) [112] initially evaluated a “staircase” RM in which PEEP was set to 25 cmH₂O for one minute, 35 cmH₂O for one minute, and then 45 cmH₂O for two minutes, followed by a decremental PEEP titration; the comparison group received no RM and a low PEEP/FiO₂ strategy. The ART RM strategy was modified halfway through enrollment to a less aggressive RM due to three cardiac arrests attributed to the intervention. The ART trial was considered the highest quality among included trials. One additional potentially eligible trial [132] was excluded from analyses

as it enrolled only burn patients with ARDS, a unique, population thought not to be generalizable. When considering the impact of the intervention on ICU mortality, five trials were included; the trial by Chung not reporting this outcome was excluded, while the trial by Huh et al. not included in the hospital mortality meta-analysis was included.

The ART was the only trial meeting moderate-high quality standards and entering the primary analysis. In this study, the analysis of mortality at different time points provided non homogeneous findings (Supplementary Materials), but there was a suspicion of increased mortality at 6 months. However, combined in the meta-analysis (our secondary analysis), the intervention showed neither harmful nor beneficial effects on mortality. The analysis of heterogeneity was inconclusive.

The analysis of barotrauma, instead, showed an outlier position of the ART trial, with a clear harmful effect (RR 3.56, 95% CI 1.64–7.73), quite different from the other trials combined in a separate meta-analysis (RR 0.60, 95% CI 0.25–1.41) (see Supplementary Materials). This finding strongly supported our recommendation against the use of recruitment high-pressure recruitment maneuvers.

VFDs were reported by three trials [112, 129, 130]. We based our primary analysis on the ART trial [112] which showed a significant reduction in the mean number of VFD in the intervention arm, given that the other two trials reported medians and interquartile ranges and thus could not be meta-analyzed with the ART trial.

Recommendation 6.3

We **recommend against** use of prolonged high-pressure recruitment maneuvers (defined as airway pressure maintained ≥ 35 cmH₂O for at least one minute) to reduce mortality of patients with ARDS.
Strong recommendation; moderate level of evidence against.
This recommendation applies also to ARDS from COVID-19.
Strong recommendation; low level of evidence against for indirectness.

Question 6.4: In patients with ARDS undergoing invasive mechanical ventilation, does routine use of brief high-pressure recruitment maneuvers, compared to no use of brief high-pressure recruitment maneuvers, reduce mortality?

Summary of the evidence

A brief high-pressure RM was defined as a strategy intended to facilitate lung recruitment in which airway pressure of ≥ 35 cmH₂O was maintained for less than one minute. Three trials were included in analyses. Kacmarek et al. ($n=200$) [133] compared a series of two

brief RMs (transient increase in PEEP to 35–45 cmH₂O) interspersed with a decremental PEEP trial versus no RM with a low PEEP/FiO₂ table. LOVS ($n=983$) [107] utilized a single brief RM (40 cmH₂O breath hold for 40 seconds; subsequent RMs allowed for ventilator circuit disconnect) with a high PEEP/FiO₂ table compared to no RM with a low PEEP/FiO₂ table. Xi et al. [134] compared a brief RM (40 cmH₂O breath hold for 40 seconds) repeated every 8 hours for up to five days versus no RM. The trial by Xi et al. did not standardize PEEP in either group, and was thus considered separately.

Mortality did not differ significantly between treatment groups in any of the three trials individually, nor in meta-analysis pooling the two trials with standardized PEEP (pooled RR 0.89; 95% CI 0.77–1.04). VFDs did not differ significantly between treatment groups in Kacmarek et al. or Xi et al. VFD was not reported in LOVS.

Barotrauma did not differ significantly between treatment groups in any of the three trials individually, nor in meta-analysis pooling the two trials with standardized PEEP (pooled RR 1.14; 95% CI 0.81–1.62).

Considering hemodynamic instability, in Kacmarek et al. there was no significant difference in incidence of hypotension, arrhythmia, or cardiac arrest. In LOVS, hemodynamics was reported as days of vasopressor use and number of vasopressors per day in use and were comparable between groups. Hemodynamic effects were not well characterized in Xi et al.

Absence of evidence in favor or against the use of recruitment maneuvers, the potential safety issues led to a weak recommendation against their routine use.

Recommendation 6.4

We **suggest against** routine use of brief high-pressure recruitment maneuvers (defined as airway pressure maintained ≥ 35 cmH₂O for less than one minute) to reduce mortality in patients with ARDS.
Weak recommendation; high level of evidence of no effect.
This suggestion applies also to ARDS from COVID-19.
Weak recommendation; moderate level of evidence of no effect for indirectness.

Expert opinion on clinical application of recruitment maneuvers

Hypotension and desaturation are the most common adverse events described during or immediately after an RM, each occurring in roughly 10% of patients undergoing an RM [119]. Bradycardia, presumably vagally mediated, also may occur [135]. Clinical trial data indicate prolonged high-pressure RMs increase risks, leading not only to hemodynamic instability but increased risk of barotrauma and cardiac arrest [112]. These clinically

important risks outweigh potential benefits and led to the recommendation against their use.

Brief high-pressure RMs also may produce transient, potentially reversible hypotension and bradycardia [115, 135] which can result from acute right heart failure. Existing data do not support routine use of brief RMs, likely because lung mechanical effects from briefly raising airway pressure are transient unless accompanied by other maneuvers to prevent progressive collapse [136]. Nevertheless, brief RMs may have a limited role in attempt to reverse hypoxemia in situations where desaturation is likely caused by derecruitment, for example after ventilator disconnect, suctioning, bronchoscopy or patient repositioning. If performed, brief high-pressure RMs should only be done with a plan to abort the maneuver immediately if cardiovascular instability ensues.

Unresolved questions and research gaps

Brief recruitment maneuvers in the form of “sigh” breaths, performed periodically one or more times every few minutes, may prevent progressive derecruitment that can occur with low airway pressure, low tidal volume ventilation [127, 137]. Whether such periodic maneuvers attenuate ventilation-induced lung injury or pose safety risks, how often they might need to be performed to afford such lung protection (if any), and in whom they might afford benefit based on potential for lung recruitment all warrant further investigation.

Domain 7: Prone positioning

Question 7.1: In intubated patients with ARDS, does prone position compared to supine position reduce mortality?

Background

Prone position was proposed for patients with acute hypoxemic respiratory failure and ARDS in the 1970s. Physiological benefits include improvement of oxygenation, better homogenization of lung stress, and decreased right ventricular strain. Over the years, several trials were conducted comparing prone to supine position, with improved designs on the basis of the critical analysis of previous ones [138–144]. Thus, progressively more hypoxemic patients were selected, the duration of prone ventilation cycles increased, and protective ventilation was combined with pronation. In 2013, the PROSEVA trial demonstrated a clear protective effect of prone ventilation in patients with moderate-to-severe ARDS [9]. In 2017, the ESICM and the American Thoracic Society (ATS) provided recommendations for the use of prone ventilation in ARDS [13] based on both aggregated and individual patient data meta-analysis

[10] that included the largest four trials [138, 139, 143, 144]. In the aggregated data meta-analysis, the overall result was non-significant; however, in studies that used duration of proning longer than twelve hours or included patients with $\text{PaO}_2/\text{FiO}_2 \leq 200$ mmHg, a statistically significant mortality reduction was found. The individual patient meta-analysis [10] identified a survival benefit in patients with $\text{PaO}_2/\text{FiO}_2 \leq 100$ mmHg. However, this subgroup analysis did not allow any definitive conclusion since the benefits of randomization are not maintained in subgroups (and only one study stratified patients according to the degree of hypoxemia [144]). In general, subgroup analyses in meta-analysis have an exploratory nature, and results should be interpreted cautiously. There were no RCTs identified specifically addressing proning of mechanically ventilated patients in COVID-19.

Summary of the evidence

We based our analysis on the eight trials selected in the previous 2017 guidelines since no further trials on this topic have been conducted since. However, we excluded the 2004 trial that was not restricted to ARDS [139]. Meta-analysis was conducted for the outcome of short-term mortality, defined as either at 28 days or in the ICU, and separately for 90-days mortality.

Relevant clinical heterogeneity was found among the studies in terms of modality of ventilation, dose of daily prone ventilation, patient selection, and timing of application of prone positioning.

Short-term mortality did not differ between prone and supine position (RR 0.79 95% CI [0.61–1.03]). In the subgroup of the first five trials, the short-term mortality did not differ between supine and prone positioning (0.91 [0.77–1.08]). However, the short-term mortality was significantly lower in the prone positioning group of the PROSEVA trial (0.49 [0.35–0.69]), with a statistically significant interaction test (supplement materials).

Longer-term mortality did not differ between prone and supine position (0.81 [0.64–1.02]). In the subgroup of the first five trials the longer-term mortality did not differ (0.93 [0.79–1.09]). 90-days mortality was significantly improved by proning in the PROSEVA trial (0.58 [0.44–0.76]) ($p < 0.01$). In this case as well the interaction test turned out to be statistically significant. The unique findings of the PROSEVA trial were further highlighted by a cumulative meta-analysis that investigated the results of meta-analyses carried over time (Supplementary Materials). Further, the analysis of heterogeneity performed using the double-p plot approach [145], identified the PROSEVA trial as a clear outlier.

Our primary analysis was thus based on the individual evaluation of findings from the PROSEVA trial. The secondary analysis included, instead, all the trials.

Recommendation 7.1

We **recommend** using prone position as compared to supine position for patients with moderate-severe ARDS (defined as $\text{PaO}_2/\text{FiO}_2 < 150$ mmHg and $\text{PEEP} \geq 5$ cmH_2O , despite optimization of ventilation settings) to reduce mortality.

Strong recommendation, high level of evidence in favor.

This recommendation applies also to ARDS from COVID-19.
Strong recommendation; moderate level of evidence in favor for indirectness.

Expert opinion on clinical application

The overall risk–benefit balance favors prone position used according to the PROSEVA trial criteria, particularly given that its application is feasible in most ICUs with adequately skilled and staffed caregivers when paying careful attention to the risk of pressure-related skin complications.

Unresolved questions and research gaps

It is unlikely that a trial comparing prone to supine will be conducted in moderate-severe COVID-related ARDS given the lack of equipoise in the field at present. A trial is ongoing in France in adult intubated patients with mild to moderate ARDS (NCT05056090).

Question 7.2: In patients with moderate-severe ARDS, when should prone positioning be started to reduce mortality?

Background

No specific trial was designed to explore the role of pre-determined criteria in the decision to start prone position. Therefore, the evidence used for this question is the same as that for previous the question.

Recommendation 7.2

We **recommend** starting prone position in patients with ARDS receiving invasive mechanical ventilation early after intubation, after a period of stabilization during which low tidal volume is applied and PEEP adjusted and at the end of which the $\text{PaO}_2/\text{FiO}_2$ remains < 150 mmHg; and proning should be applied for prolonged sessions (16 consecutive hours or more) to reduce mortality.

Strong recommendation; high level of evidence in favor.

This recommendation applies also to ARDS from COVID-19.
Strong recommendation; moderate level of evidence in favor for indirectness.

Expert opinion on clinical application

The current recommendation is based on the evidence obtained from one trial (PROSEVA). The stabilization period before proning should take into account the time to optimize the ventilator settings and hemodynamics. Continuing prone position even if there is no significant initial improvement in oxygenation is based on the potential of prone position to protect the lung by homogenization of lung stress and potentially improving trajectory of recovery.

Unresolved questions and research gaps

There is no trial comparing different durations of prone position and no trial testing strategies other than oxygenation to determine when to cease proning sessions. The difference in $\text{PaO}_2/\text{FiO}_2$ ratio between prone and subsequent supine position could be used to guide when to cease prone position. Moreover, using respiratory mechanics, e.g., keeping driving pressure within safe ranges, in addition to oxygenation and/or markers of dead-space ventilation, may be taken into account in the decision to stop the sessions. The effect of prolonged sessions of proning in patients showing minimal improvement in gas exchange should be further evaluated.

Question 7.3: In non intubated patients with AHRF, does awake prone positioning (APP) as compared to supine positioning reduce intubation or mortality?

Background

During the recent COVID-19 pandemic, with the spread of non-invasive respiratory support strategies in the wards and ICUs, so-called “awake proning” in non-mechanically ventilated patients was often performed and became the focus of several clinical trials [146]. Indeed, all the high-quality evidence from RCTs derived from studies enrolling only COVID-19 patients.

Summary of the evidence

Three trials comparing APP to a control group in the supine position, all in COVID-19 patients [147–149], were included in the meta-analysis. One of the studies was a meta-trial including six randomized controlled trials conducted in six different countries (Canada, France, Ireland, Mexico, Spain, United States of America) harmonizing the protocols and combining the data [147]. Most patients enrolled in all three trials were treated with HFNO. Specifically, the proportion of patients treated with HFNO at time of inclusion was 100% APP vs 100% control in the meta-trial [147], 86.1% APP vs 74.1% control in the Swedish study [148], and 72.2% APP vs 67.7% control in the third study [149]. The corresponding rates

of non-invasive ventilation were 0% vs 0% [147], 58.3% vs 69.2% [148], and 5.9% vs 10.3% [149].

In the primary analysis, the meta-trial was split into its six individual components and, therefore, performed the meta-analysis over eight trials. Furthermore, the trial performed in Mexico was removed from the meta-trial because it was associated with a significant reduction in intubation rate compared to the five other trials; also, it provided a twofold higher duration of APP than the other trials, and it behaved as an outlier on a plot that highlighted the inconsistency across the studies in the meta-trial. Therefore, the primary analysis was done on two subgroups: one with seven trials and one with Mexico trial only.

The main outcome of the meta-trial was a composite endpoint including mortality and intubation at 28 days. To be reliable, the elements of a composite outcome needs to fulfill three conditions: have similar clinical relevance, occur with the same frequency, and should be affected similarly by the trailed intervention. The composite endpoint selected in the trials included in our review did not meet these criteria and, hence, we investigated separately intubation and mortality, which were at either 28 or 30 days.

APP significantly reduced the risk of intubation in both the primary analysis, focused on five trials with the lower level of bias, and the secondary analysis including all 8 studies (RR 0.84 [0.94–0.87] and 0.84 [0.73–0.96], respectively). In the subgroup of seven trials, the intubation rate did not differ between APP and control groups (0.89 [0.77–1.04]); in contrast, the trial in Mexico reported a significantly lower risk of intubation in APP (0.7 [0.54–0.9]). Although the interaction test was statistically non-significant, a careful the analysis of heterogeneity revealed the trial in Mexico to be an outlier and APP had no overall effect on mortality.

Recommendation 7.3

We **suggest** awake prone positioning as compared to supine positioning for non-intubated patients with COVID-19-related AHRF to reduce intubation.

Weak recommendation; low level of evidence in favor.

We are **unable to make a recommendation** for or against APP for non-intubated patients with COVID-19-related AHRF to reduce mortality.

No recommendation; moderate level of evidence of no effect.

We are **unable to make a recommendation** for or against APP for patients with AHRF not due to COVID-19.

No recommendation; no evidence.

Expert opinion on clinical application

APP can be considered in patients with AHRF due to COVID-19. Close monitoring is required to avoid

delaying intubation and to regularly assess and manage comfort and tolerance.

Unresolved questions and research gaps

More data are needed on the effect of APP in non-COVID-19 patients with AHRF. Selecting the adequate outcome is an issue, as a composite score has some limitations; mortality is likely the most relevant outcome. Other issues with APP that need clarification include the location (ICU vs non-ICU), the optimal respiratory support (HFNO, CPAP, NIV) and the impact of APP on inspiratory effort, work of breathing and potential lung injury.

Domain 8: Neuromuscular blocking agents

Question 8.1: Does the routine use of a continuous infusion of neuromuscular blocking agents (NMBA) in patients with moderate-to-severe ARDS not due to COVID-19 or moderate-to-severe ARDS due to COVID-19 reduce mortality?

Background

The administration of NMBA to mechanically ventilated patients with ARDS reduces the work of breathing and patient-ventilator asynchrony and may affect outcome [150]. However, prolonged use of NMBA is also associated with neuromuscular weakness and requires deep sedation, which itself can result in adverse outcomes [151, 152]. More than a decade ago, the ACURASYS trial reported that the early administration of a 48-h infusion of NMBA in patients with moderate-to-severe ARDS ($\text{PaO}_2/\text{FiO}_2 < 150$ mmHg with $\text{PEEP} \geq 5$) resulted in lower mortality than a strategy of deep sedation without routine NMBA use, after an adjusted analysis [153]. Three other smaller trials with similar inclusion criteria and treatment protocols showed benefit with routine NMBA use [154–156]. However, ICU practices have evolved since these trials, with emphasis on lighter sedation and earlier return to spontaneous breathing.

In the recent ROSE trial, which randomized patients with moderate-to-severe ARDS to a 48h continuous infusion of NMBA with concomitant deep sedation (intervention group) or to a usual-care approach without routine neuromuscular blockade and with lighter sedation targets (control group), there was no significant difference in mortality at 90 days [157]. There has been an increased use of NMBA infusions in patients with COVID-19 ARDS who are mechanically ventilated, most commonly to abolish vigorous spontaneous efforts and decrease the generation of high transpulmonary pressures that could aggravate self-inflicted lung

injury or asynchronies [158]. However, randomized trials on NMBA use in patients with COVID-19 are lacking. Given that the ROSE trial excluded a significant number of patients already receiving NMBA, the benefit of early continuous NMBA remains unclear.

Summary of the evidence

Two studies provided different results, for the 90-days outcome with the ACURASYS trial reporting a protective effect [153], and the latest ROSE trial demonstrating a non-significant result [157]. The ACURASYS trial sample size calculation was based on the expectation of a large mortality reduction (15%). The 9% reduction found was not statistically significant ($p=0.08$). The power for the observed delta was 42%, and 842 patients would have been required assuming a power of 80% given the same difference. The ROSE trial assumed an 8% mortality reduction, and under the assumption of a 90% power, the randomization of about 1400 patients was planned. A meta-analysis of the two studies found an overall non-significant result, with a heterogeneity estimate that was high (I^2 56%), although the imprecision was such that we could not rule out either low or high heterogeneity. The evaluation of overall evidence was moderate against (according to the GRADE after rating down for imprecision), and according to the risk of biases (RoB) 2 assessment tool, there was an overall low risk of bias.

When analyzing the 28-days or ICU mortality, five trials were included [153–157]. Of these, three reported 28-days mortality, and two ICU mortality [153, 157]. Meta-analysis identified no significant mortality reduction in the NMBA group compared to no NMBA, with a 0.80 relative risk (95% CI 0.57, 1.04), p value 0.086.

There were several differences between the two larger studies [153, 157] highlighted. Prone ventilation was less common in the ROSE trial compared to the ACURASYS trial (15.8 vs. 44.8%). The sedation targets for controls were lighter in the ROSE trial, possibly related to a lower number of serious cardiovascular events (14 vs. 4, intervention arm vs. controls) and mortality in the control arm. Higher PEEP strategies were used in the ROSE trial, with an unclear effect on mortality. It is also interesting that the mortality in the intervention arm in the ROSE study was not different from those the control arm in the ROSE and ACURASYS trials. There are two potential explanations for this finding. First, it is possible that patients had the same severity in the two trials, but the intervention overall was not effective in the ROSE trial because the interventions were substantially different, e.g., same pharmacological approach but different ventilatory approach such as PEEP protocols or ventilation in the prone position. Alternatively, it may have been that

patients were less severely ill in the ACURASYS trial, but sedation was heavier in the control group (compared to the ROSE trial) causing higher mortality rates.

There were no randomized controlled trials in patients with ARDS due to COVID-19. Only indirect evidence from non-COVID studies was available.

Recommendation 8.1

We **recommend against** the *routine* use of continuous infusions of NMBA to reduce mortality in patients with moderate-to-severe ARDS not due to COVID-19.

Strong recommendation, moderate level of evidence.

We are **unable to make a recommendation** for or against the *routine* use of continuous infusions of NMBA to reduce mortality in patients with moderate-to-severe ARDS due to COVID-19.

No recommendation; no evidence.

Expert opinion on clinical application

In the ACURASYS trial, the use of prone ventilation without neuromuscular blockade was associated with deeper sedation targets, which may have contributed to the increased mortality in the control arm [153]. A clear protective effect for pneumothorax was found in the NMBA group compared to controls in the four studies included [153–155, 157]. This finding may support the use of NMBA in those patients at risk of developing a pneumothorax.

Unresolved questions and research gaps

Future research should prioritize other outcomes including successful extubation, re-intubation, paralysis recall, ICU acquired weakness and health-related quality of life and the specific role on NMBA in prone position. Another important area of research is the recognition of poor patient-ventilator interaction in invasively ventilated ARDS patients, as this has potential effects on clinical outcomes and may represent a possible indication for the administration of NMBA. The views of patients and caregivers should be central to determining future research questions and outcomes.

Domain 9: Extracorporeal life support

Question 9.1: In adult patients with severe acute respiratory distress syndrome (ARDS) or COVID-19 does veno-venous extracorporeal membrane oxygenation (VV-ECMO) compared with conventional ventilation improve outcomes?

Background

VV-ECMO is used to support or replace gas exchange. During ECMO, blood is passed through a “membrane lung” which facilitates exchange of oxygen and carbon

dioxide by diffusion. Technological improvements have led to improved gas exchange and reduced complications [159]. ECMO has been used for patients with severe ARDS including more recently patients with COVID-19. High-volume expert centers report better outcomes with ECMO [160]. It is likely that an overall package of care delivered alongside the use of ECMO, including lung-protective ventilation and prone positioning, is required to achieve improved outcomes in patients receiving ECMO.

Summary of the evidence

Two randomized controlled trials informed the basis of these recommendations. The CESAR trial included 180 patients, and the EOLIA trial included 249 patients with ARDS [161]. The EOLIA inclusion criteria were as follows: a $\text{PaO}_2/\text{FiO}_2 < 50$ mmHg for > 3 hours, or a $\text{PaO}_2/\text{FiO}_2$ of < 80 mmHg for > 6 hours, or a pH of < 7.25 with a PaCO_2 of ≥ 60 mmHg for > 6 hours, with the respiratory rate increased to 35 breaths per minute and mechanical ventilation settings adjusted to keep a plateau pressure of ≤ 32 cmH₂O [162].

These studies included patients with severe ARDS of any etiology (average $\text{PaO}_2/\text{FiO}_2$ values were approximately 75 mmHg), though both were conducted prior to the COVID-19 pandemic. The EOLIA and CESAR trials were considered clinically sufficiently homogenous to be meta-analytically combined. According to the RoB2 tool, there was a high risk of bias with the CESAR trial, as about one-quarter of patient in the intervention arm did not receive ECMO.

Meta-analysis identified a significant decrease in 60-day mortality in patients receiving VV-ECMO compared to conventional mechanical ventilation (RR 0.72; 95% CI 0.57–0.91; moderate confidence). The protective effect was consistent across the 90-days mortality outcomes as well as a composite outcome of mortality and therapeutic failure at 60 days. Observational studies, including a post-hoc Bayesian analysis of the EOLIA study [163], mostly confirmed a protective effect of ECMO [163–171]. However, the very low evidence that they provided did not substantially affect the moderate quality of evidence provided by the meta-analysis of the two randomized trials. The observational studies were not combined in a meta-analysis due to methodological limitations.

There were no randomized controlled trials in patients with COVID-19. The evidence for ECMO in COVID-19 was assessed as weak in favor, being downgraded due to the indirectness of the available RCT evidence. Observational studies in COVID-19 mostly showed a protective

effect of ECMO in short-term survival [167, 169–171]. We did not combine the observational studies in a meta-analysis due to methodological limitations.

The use of ECMO is associated with the risk of serious bleeding. In the EOLIA trial, higher rates of bleeding events leading to blood transfusion (46 vs. 28%) and of severe thrombocytopenia (27 vs. 16%) in the intervention arm were reported. However, less ischemic strokes (5% absolute risk reduction; 95% CI, 2–10%) and no differences in hemorrhagic strokes was found [162].

Recommendation 9.1

We **recommend** that patients with severe ARDS not due to COVID-19 as defined by the EOLIA trial eligibility criteria, should be treated with ECMO in an ECMO center which meets defined organizational standards, adhering to a management strategy similar to that used in the EOLIA trial.

Strong recommendation, moderate level of evidence in favor

This recommendation applies also to patients with severe ARDS due to COVID-19.

Strong recommendation; low level of evidence in favor for indirectness.

Expert opinion on clinical application

A network of ECMO centers with expertise in this technique is likely to be required to effectively provide ECMO. With centralization of patients from non-ECMO centers, an ECMO team with capacity to transfer patients on ECMO (mobile ECMO) is required. Resources and skills to deliver such a service are required.

It is unlikely that an RCT of ECMO in severe ARDS due to COVID-19 will be conducted. In patients with ARDS due to COVID, early mortality up to 90-days was similar to non-COVID ARDS patients when ECMO was initiated in experienced centers. Although patients with COVID will not have been included in the RCTs which form the basis of these recommendations, there is biological plausibility that ARDS due to non-COVID and COVID should have similar outcomes with ECMO. However, the rate of serious and prolonged multidimensional disability, particularly in patients with COVID-19 may be significant, although specific attribution to ECMO rather than severe ARDS is unknown.

Unresolved questions and research gaps

Future research should additionally prioritize long-term multidimensional outcomes for patients and families and ascertain ECMO-specific morbidities. The views of patients and carers should be central to determining future research questions and outcomes.

Table 2 Summary of recommendations



















HIGH FLOW NASAL OXYGEN	
Q1 In non-mechanically ventilated patients with acute hypoxemic respiratory failure (AHRF) not due to cardiogenic pulmonary edema or acute exacerbation of chronic obstructive pulmonary disease (COPD), does high flow nasal oxygen (HFNO) compared to conventional oxygen therapy (COT) reduce mortality or intubation?	
1	We recommend that non-mechanically ventilated patients with AHRF not due to cardiogenic pulmonary edema or acute exacerbation of COPD receive HFNO as compared to COT to reduce the risk of intubation.  MODERATE LEVEL OF EVIDENCE
2	This recommendation applies also to AHRF from coronavirus 2019 (COVID-19)  LOW LEVEL OF EVIDENCE
3	We are unable to make a recommendation for or against the use of HFNO over COT to reduce mortality.  HIGH LEVEL OF EVIDENCE
4	This recommendation applies also to AHRF from COVID-19.  MODERATE LEVEL OF EVIDENCE
Q2 In non-mechanically ventilated patients with AHRF not due to cardiogenic pulmonary edema or acute exacerbation of COPD, does HFNO compared to non-invasive ventilation (NIV) reduce mortality or intubation?	
1	We are unable to make a recommendation for or against the use of HFNO compared to continuous positive airway pressure (CPAP)/NIV to reduce intubation or mortality in the treatment of unselected patients with AHRF not due to cardiogenic pulmonary edema or acute exacerbation of COPD.  MODERATE LEVEL OF EVIDENCE FOR MORTALITY LOW LEVEL OF EVIDENCE FOR INTUBATION
2	We suggest that CPAP/NIV can be considered instead of HFNO to reduce the risk of intubation in AHRF due to COVID-19.  HIGH LEVEL OF EVIDENCE
3	No recommendation can be made for whether CPAP/NIV can decrease mortality compared to HFNO in COVID-19.  HIGH LEVEL OF EVIDENCE
CONTINUOUS POSITIVE AIRWAY PRESSURE / NON-INVASIVE VENTILATION	
Q1 In non-mechanically ventilated patients with AHRF not due to cardiogenic pulmonary edema, obesity hypoventilation or acute exacerbation of COPD, does CPAP/NIV, as compared to COT reduce mortality or intubation?	
1	We are unable to make a recommendation for or against the use of CPAP/NIV compared to COT for the treatment of AHRF (not related to cardiogenic pulmonary edema or acute exacerbation of COPD) to reduce mortality or to prevent intubation.  HIGH LEVEL OF EVIDENCE FOR MORTALITY MODERATE LEVEL OF EVIDENCE FOR INTUBATION
2	We suggest the use of CPAP over COT to reduce the risk of intubation in patients with AHRF due to COVID-19.  LOW LEVEL OF EVIDENCE
3	We are unable to make a recommendation for or against the use of CPAP over COT to reduce mortality in AHRF due to COVID-19.  MODERATE LEVEL OF EVIDENCE
<p>LEVELS OF EVIDENCE:  NO EVIDENCE /  VERY LOW LEVEL /  LOW LEVEL /  MODERATE LEVEL /  HIGH LEVEL</p> <p>  NO RECOMMENDATION  STRONG RECOMMENDATION  WEAK RECOMMENDATION </p>	

Table 2 (continued)

<p>Q2 In patients being treated with CPAP/NIV for AHRF, does the use of a helmet interface as compared to face mask reduce intubation or mortality?</p>	<p>1 We are unable to make a recommendation for or against the use of helmet interface for CPAP/NIV as compared to face mask to prevent intubation or reduce mortality in patients with AHRF.</p>	<p> VERY LOW LEVEL OF EVIDENCE</p>
<p>Q3 In patients with AHRF, does NIV as compared to CPAP reduce mortality or intubation?</p>	<p>1 We are unable to make a recommendation for or against the use of NIV compared to CPAP for the treatment of AHRF.</p>	<p> NO EVIDENCE</p>
LOW TIDAL VOLUME VENTILATION		
<p>Q1 In adult patients with ARDS and COVID-19-related ARDS, does low tidal volume ventilation alone compared with more traditional approaches to ventilation decrease mortality?</p>	<p>1 We recommend the use of low tidal volume ventilation strategies (i.e., 4-8 ml/kg PBW), compared to larger tidal volumes (traditionally used to normalize blood gases), to reduce mortality in patients with ARDS not due to COVID-19.</p>	<p> HIGH LEVEL OF EVIDENCE</p>
<p>2 This recommendation applies also to ARDS from COVID-19.</p>	<p> MODERATE LEVEL OF EVIDENCE</p>	
POSITIVE END-EXPIRATORY PRESSURE AND RECRUITMENT MANEUVERS		
<p>Q1 In patients with ARDS undergoing invasive mechanical ventilation, does routine positive end-expiratory pressure (PEEP) titration using a higher PEEP/FiO₂ strategy compared to a lower PEEP/FiO₂ strategy reduce mortality?</p>	<p>1 We are unable to make a recommendation for or against routine PEEP titration with a higher PEEP/FiO₂ strategy versus a lower PEEP/FiO₂ strategy to reduce mortality in patients with ARDS.</p>	<p> HIGH LEVEL OF EVIDENCE</p>
<p>2 This statement applies also to ARDS from COVID-19.</p>	<p> MODERATE LEVEL OF EVIDENCE</p>	
<p>Q2 In patients with ARDS undergoing invasive mechanical ventilation, does routine PEEP titration based principally on respiratory mechanics compared to PEEP titration based principally on a standardized PEEP/FiO₂ table reduce mortality?</p>	<p>1 We are unable to make a recommendation for or against PEEP titration guided principally by respiratory mechanics, compared to PEEP titration based principally on PEEP/FiO₂ strategy, to reduce mortality in patients with ARDS.</p>	<p> HIGH LEVEL OF EVIDENCE</p>
<p>2 This statement applies also to ARDS from COVID-19.</p>	<p> MODERATE LEVEL OF EVIDENCE</p>	

LEVELS OF EVIDENCE:
NO EVIDENCE / **VERY LOW LEVEL** / **LOW LEVEL** / **MODERATE LEVEL** / **HIGH LEVEL**



NO RECOMMENDATION



STRONG RECOMMENDATION



WEAK RECOMMENDATION

Table 2 (continued)

<p>Q3 In patients with ARDS undergoing invasive mechanical ventilation, does use of prolonged high-pressure recruitment maneuvers (RMs), compared to not using prolonged high-pressure RMs, reduce mortality?</p>	<p>1 We recommend against use of prolonged high-pressure RMs (defined as airway pressure maintained ≥ 35 cmH₂O for at least one minute) to reduce mortality of patients with ARDS.</p>	 MODERATE LEVEL OF EVIDENCE
<p>2 This recommendation applies also to ARDS from COVID-19.</p>	 LOW LEVEL OF EVIDENCE	
<p>Q4 In patients with ARDS undergoing invasive mechanical ventilation, does routine use of brief high-pressure RMs, compared to no use of brief high-pressure RMs, reduce mortality?</p>	<p>1 We suggest against routine use of brief high-pressure RMs (defined as airway pressure maintained ≥ 35 cmH₂O for less than one minute) to reduce mortality in patients with ARDS.</p>	 HIGH LEVEL OF EVIDENCE
<p>2 This suggestion applies also to ARDS from COVID-19.</p>	 MODERATE LEVEL OF EVIDENCE	
PRONE POSITIONING		
<p>Q1 In intubated patients with ARDS, does prone position compared to supine position reduce mortality?</p>	<p>1 We recommend using prone position as compared to supine position for patients with moderate-severe ARDS (defined as PaO₂/FiO₂ < 150 mmHg and PEEP ≥ 5 cmH₂O, despite optimization of ventilation settings) to reduce mortality.</p>	 HIGH LEVEL OF EVIDENCE
<p>2 This recommendation applies also to ARDS from COVID-19.</p>	 MODERATE LEVEL OF EVIDENCE	
<p>Q2 In patients with moderate-severe ARDS, when should prone positioning be started to reduce mortality?</p>	<p>1 We recommend starting prone position in patients with ARDS receiving invasive mechanical ventilation early after intubation, after a period of stabilization during which low tidal volume is applied and PEEP adjusted and at the end of which the PaO₂/FiO₂ remains < 150 mmHg; and proning should be applied for prolonged sessions (16 consecutive hours or more) to reduce mortality.</p>	 HIGH LEVEL OF EVIDENCE
<p>2 This recommendation applies also to ARDS from COVID-19.</p>	 MODERATE LEVEL OF EVIDENCE	

LEVELS OF EVIDENCE:
 NO EVIDENCE / VERY LOW LEVEL / LOW LEVEL / MODERATE LEVEL / HIGH LEVEL

 NO RECOMMENDATION

 STRONG RECOMMENDATION

 WEAK RECOMMENDATION

Table 2 (continued)

<p>Q3 In non intubated patients with AHRF, does awake prone positioning (APP) as compared to supine positioning reduce intubation or mortality?</p>	<p>1 We suggest awake prone positioning as compared to supine positioning for non-intubated patients with COVID-19-related AHRF to reduce intubation.</p>	<p> LOW LEVEL OF EVIDENCE</p>
<p>2 We are unable to make a recommendation for or against APP for non-intubated patients with COVID-19-related AHRF to reduce mortality.</p>	<p> MODERATE LEVEL OF EVIDENCE</p>	
<p>3 We are unable to make a recommendation for patients with AHRF failure not due to COVID-19.</p>	<p> NO EVIDENCE</p>	
NEUROMUSCULAR BLOCKING AGENTS		
<p>Q1 Does the <i>routine</i> use of a continuous infusion of neuromuscular blocking agents (NMBA) in patients with moderate to severe ARDS not due to COVID-19 or moderate to severe ARDS due to COVID-19 reduce mortality?</p>	<p>1 We recommend against the <i>routine</i> use of continuous infusions of NMBA to reduce mortality in patients with moderate to severe ARDS not due to COVID-19.</p>	<p> MODERATE LEVEL OF EVIDENCE</p>
<p>2 We are unable to make a recommendation for or against the <i>routine</i> use of continuous infusions of NMBA to reduce mortality in patients with moderate to severe ARDS due to COVID-19.</p>	<p> NO EVIDENCE</p>	
EXTRACORPOREAL LIFE SUPPORT		
<p>Q1 In adult patients with severe ARDS or COVID-19 does veno-venous extracorporeal membrane oxygenation (VV-ECMO) compared with conventional ventilation improve outcomes?</p>	<p>1 We recommend that patients with severe ARDS not due to COVID-19 as defined by the EOLIA trial eligibility criteria, should be treated with ECMO in an ECMO centre which meets defined organisational standards, adhering to a management strategy similar to that used in the EOLIA trial.</p>	<p> MODERATE LEVEL OF EVIDENCE</p>
<p>2 This recommendation applies also to severe ARDS from COVID-19.</p>	<p> LOW LEVEL OF EVIDENCE</p>	
<p>Q2 In adult patients with ARDS, does extracorporeal carbon dioxide removal (ECCO₂R) compared with conventional ventilation improve outcomes?</p>	<p>1 We recommend against the use of ECCO₂R for the treatment of ARDS not due to COVID-19 to prevent mortality outside of randomized controlled trials.</p>	<p> HIGH LEVEL OF EVIDENCE</p>
<p>2 This recommendation applies also to severe ARDS from COVID-19.</p>	<p> MODERATE LEVEL OF EVIDENCE</p>	

LEVELS OF EVIDENCE:
NO EVIDENCE / VERY LOW LEVEL / LOW LEVEL / MODERATE LEVEL / HIGH LEVEL



NO RECOMMENDATION



STRONG RECOMMENDATION



WEAK RECOMMENDATION

Table 3 Comparison between 2017 and 2023 ARDS guidelines

	2017	2023	CHANGE IN RECOMMENDATION	COMMENTS
Definition	NOT AVAILABLE	AVAILABLE	NEW RECOMMENDATION / DOMAIN SINCE 2017	No comparison available as the 2017 guidelines did not include a Definition domain.
Phenotypes	NOT AVAILABLE	AVAILABLE	NEW RECOMMENDATION / DOMAIN SINCE 2017	No comparison available as the 2017 guidelines did not include an ARDS Phenotype domain.
High flow nasal oxygen	NOT AVAILABLE	AVAILABLE	NEW RECOMMENDATION / DOMAIN SINCE 2017	No comparison available as the 2017 guidelines did not include recommendations on high flow nasal oxygen.
Non-invasive ventilation	NOT AVAILABLE	AVAILABLE	NEW RECOMMENDATION / DOMAIN SINCE 2017	No comparison available as the 2017 guideline did not include recommendations on non-invasive ventilation.
Tidal volume	AVAILABLE	AVAILABLE	NO CHANGE	In agreement with the use of low tidal volume strategies. 2023 guidelines extend this recommendation to patients with COVID-19.
Positive end-expiratory pressure	AVAILABLE	AVAILABLE	CHANGE IN RECOMMENDATION	2017: suggest that adult patients with moderate or severe ARDS receive higher rather than lower levels of PEEP. 2023: analysis of data does not allow to make a recommendation for or against higher PEEP strategy.
Recruitment maneuvers	AVAILABLE	AVAILABLE	CHANGE IN RECOMMENDATION	2017: suggest that adult patients with ARDS receive RMs. 2023: recommend against RMs due to increased mortality and risks.
Oscillatory ventilation	AVAILABLE	NOT AVAILABLE	NOT CONSIDERED	2017: recommend that HFOV not be used routinely in patients with moderate or severe ARDS. 2023: not examined given the absence of studies since 2017 and the lack of use of HFVO in adults.
Prone position	AVAILABLE	AVAILABLE	NO CHANGE	Agreement with the use of prone position in ARDS. Additions in 2023 are the use of awake proning and the use in COVID-19.
Neuromuscular blockade	NOT AVAILABLE	AVAILABLE	NEW RECOMMENDATION / DOMAIN SINCE 2017	No comparison available as the 2017 guidelines did not include recommendations on neuromuscular blockade.
Extracorporeal membrane oxygenation	AVAILABLE	AVAILABLE	CHANGE IN RECOMMENDATION	2017: additional evidence is necessary to make a definitive recommendation. 2023: recommend ECMO in patients with severe ARDS.
Extracorporeal CO₂ removal	NOT AVAILABLE	AVAILABLE	NEW RECOMMENDATION / DOMAIN SINCE 2017	No comparison available as the 2017 guidelines did not include recommendations on extracorporeal CO ₂ removal. 2023 guidelines recommend against ECCO ₂ R in ARDS.



ARDS: acute respiratory distress syndrome; **COVID-19:** coronavirus disease 2019; **ECCO₂R:** Extracorporeal CO₂ Removal; **ECMO:** extracorporeal membrane oxygenation; **HFOV:** High-frequency oscillatory ventilation; **PEEP:** positive end-expiratory pressure; **RM:** recruitment maneuver

Question 9.2: In adult patients with ARDS, does extracorporeal carbon dioxide removal (ECCO₂R) compared with conventional ventilation improve outcomes?

Background

ECCO₂R aims to remove carbon dioxide via an extracorporeal circuit. ECCO₂R uses lower extracorporeal blood flow rates (typically between 200 and 1500 mL/min) compared to ECMO because the blood flow rates needed to remove CO₂ are much lower than required to achieve

adequate oxygenation. Although ECCO₂R is often defined based on the flow rate through the extracorporeal circuit, it has been suggested that ECCO₂R should be defined based on the clinician's intended use [172]. The primary aim of ECCO₂R in ARDS is to facilitate a reduction in injurious mechanical ventilation.

Summary of the evidence

Two RCTs formed the basis of these recommendations. The Xtravent trial included 79 patients with ARDS with

PaO₂/FiO₂ < 200 mmHg who received CO₂ removal using a “pumpless” arterio-venous (approximately 1–2 L/min) approach [173]. The REST trial included 412 hypoxemic patients (PaO₂/FiO₂ < 150 mmHg) who received CO₂ removal using a veno-venous low flow (approximately 450 ml/min) approach. The majority of patients had ARDS (approximately 60%) [174]. The Xtravent and REST trials were considered clinically sufficiently homogenous to be meta-analytically combined. There were methodological concerns with the Xtravent trial and some methodological concerns for the REST trial according to the RoB2 assessment. When considering ventilator-free days, methodological concerns were recognized due to lack of blinding.

In meta-analysis of these 2 trials, ECCO₂R did not reduce mortality (RR 1.03; 95% CI, 0.82–1.3; high confidence). Patients receiving ECCO₂R had fewer ventilator-free days to day 28 (mean difference –1.21; 95% CI –3.77 to 1.34; moderate confidence). There were no randomized controlled trials in patients with COVID-19. Evidence was considered applicable to COVID patients although this was not directly investigated and therefore the evidence was downgraded due to the indirectness of the available RCT evidence. The REST trial reported increased serious side-effects attributable to ECCO₂R with nine patients (4.5%) having a cerebral hemorrhage and six patients (3%) having extracranial bleeding compared to none and one (0.5%), respectively, in the control arm [174].

Recommendation 9.2

We **recommend against** the use of ECCO₂R for the treatment of ARDS not due to COVID-19 to prevent mortality outside of randomized controlled trials.

Strong recommendation, high level of evidence of no effect.

This recommendation applies also to patients with severe ARDS due to COVID-19.

Strong recommendation; moderate level of evidence of no effect for indirectness.

Expert opinion on clinical application

The Xtravent trial had blood flows of 1–2 L/min and the REST trial of approximately 450 mL/min. A lower blood flow rate of approximately 500 mL (or approximately 25% CO₂ removal) may be insufficient to achieve a sufficient reduction in injurious ventilation. The resource requirement for ECCO₂R in the REST trial (blood flow < 500 mL) was estimated to be comparable to that of CRRT; however, with higher blood flows the delivery of ECCO₂R requires competencies similar to ECMO centers.

Unresolved questions and research gaps

Although current evidence is against the effectiveness of ECCO₂R, uncertainty about the role of ECCO₂R remains. Further research is needed to identify if a specific population of ARDS patients may respond to ECCO₂R. In addition, the technique may be device-dependent for both efficacy and safety. Ongoing randomized controlled trials may provide further evidence in this field. When these trials conclude, the ARDS ESICM guidelines group will review and update the current recommendation. Future research should additionally prioritize long-term multidimensional outcomes for patients and families and ascertain ECCO₂R specific morbidity. The views of patients and carers should be central to determining future research questions and outcomes.

Conclusions

In conclusion, these guidelines present 21 evidence-based recommendations (summarized in Table 2) including definition, phenotyping and the respiratory management of ARDS. A summary table comparing the changes in scope and recommendations compared with the 2017 ARDS guidelines are presented in Table 3. Finally, research priorities are identified for future studies.

Supplementary Information

The online version contains Supplementary Materials available at <https://doi.org/10.1007/s00134-023-07050-7>.

Author details

¹ Department of Anesthesia, Critical Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. ² Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy. ³ Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, USA. ⁴ Department of Adult Critical Care, Guy's and St Thomas' NHS Foundation Trust, London, UK. ⁵ Centre for Human and Applied Physiological Sciences, King's College London, London, UK. ⁶ Operative Unit of Anesthesia and Intensive Care, S. Martino Hospital, Belluno, Italy. ⁷ Hospital das Clinicas, Universidade de São Paulo, São Paulo, Brazil. ⁸ Department of Anesthesiology Intensive Care and Emergency Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. ⁹ Università Cattolica del Sacro Cuore, Rome, Italy. ¹⁰ Intensive Care Department, Ministry of the National Guard - Health Affairs, Riyadh, Kingdom of Saudi Arabia. ¹¹ King Saud bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia. ¹² King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia. ¹³ Department of Anesthesia and Intensive Care, San Giovanni Bosco Hospital, Torino, Italy. ¹⁴ Center for Acute Respiratory Failure and Division of Pulmonary, Allergy and Critical Care Medicine, Columbia University, New York, NY, USA. ¹⁵ Centre for Medical Sciences - CISMed, University of Trento, Trento, Italy. ¹⁶ Department of Anesthesia and Intensive Care, Santa Chiara Hospital, APSS Trento, Trento, Italy. ¹⁷ Intensive Care Medicine, University College London, NIHR University College London Hospitals Biomedical Research Centre, London, UK. ¹⁸ Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK. ¹⁹ Intensive Care, Amsterdam UMC, Location AMC, University of Amsterdam, Amsterdam, The Netherlands. ²⁰ Keenan Research Center, Li Ka Shing Knowledge Institute, Unity Health Toronto, Toronto, Canada. ²¹ Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Canada. ²² Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD, USA. ²³ Department of Medicine, Division of Critical Care, Unity Health Toronto - Saint Michael's Hospital, Toronto, Canada. ²⁴ Li Ka Shing Knowledge Institute, St Michael's

Hospital, Toronto, Canada. ²⁵ Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada. ²⁶ Sorbonne Université, INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition, F-75013 Paris, France. ²⁷ Service de Médecine Intensive-Réanimation, Institut de Cardiologie, APHP Sorbonne Université Hôpital Pitié-Salpêtrière, F-75013 Paris, France. ²⁸ Department of Intensive Care, CHIREC Hospitals, Université Libre de Bruxelles, Brussels, Belgium. ²⁹ Sorbonne Université, INSERM, UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, Paris, France. ³⁰ AP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Université, site Pitié-Salpêtrière, Service de Médecine Intensive – Réanimation (Département R3S), Paris, France. ³¹ Shaare Zedek Medical Center and Hebrew University Faculty of Medicine, Jerusalem, Israel. ³² Department of Medicine, Division of Respiratory and Critical Care, Toronto General Hospital Research Institute, University Health Network, Toronto, Canada. ³³ Departments of Medicine and Physiology, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada. ³⁴ CHU De Poitiers, Médecine Intensive Réanimation, Poitiers, France. ³⁵ INSERM, CIC-1402, IS-ALIVE, Université de Poitiers, Faculté de Médecine et de Pharmacie, Poitiers, France. ³⁶ Department of Anesthesiology, University Medical Center Göttingen, Göttingen, Germany. ³⁷ University of Lyon, Lyon, France. ³⁸ Institut Mondor de Recherches Biomédicales, INSERM 955 CNRS 7200, Créteil, France. ³⁹ Critical Care and Respiratory Medicine, University Health Network, Toronto General Research Institute, Institute of Medical Sciences, Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Canada. ⁴⁰ The Australian and New Zealand Intensive Care Research Center, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia. ⁴¹ Department of Intensive Care, Alfred Health, Melbourne, Australia. ⁴² Division of Pulmonary, Allergy and Critical Care Medicine, Oregon Health and Science University, Portland, OR, USA. ⁴³ Anesthesia and Critical Care Department (DAR-B), Saint Eloi Teaching Hospital, University of Montpellier, Research Unit: PhyMedExp, INSERM U-1046, CNRS, 34295 Montpellier, France. ⁴⁴ Laboratory of Translational Intensive Care, Erasmus Medical Center, Rotterdam, The Netherlands. ⁴⁵ Department of Pneumology and Critical Care Medicine, Cologne-Merheim Hospital, ARDS and ECMO Centre, Kliniken Der Stadt Köln gGmbH, Witten/Herdecke University Hospital, Cologne, Germany. ⁴⁶ Department of Intensive Care Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. ⁴⁷ Makerere University College of Health Sciences, School of Medicine, Department of Anesthesia and Intensive Care, Kampala, Uganda. ⁴⁸ Anesthesia and Intensive Care Medicine, School of Medicine, College of Medicine Nursing and Health Sciences, University of Galway, Galway, Ireland. ⁴⁹ Anesthesia and Intensive Care Medicine, Galway University Hospitals, Saolta University Hospitals Groups, Galway, Ireland. ⁵⁰ Intensive Care Department, Hospital Universitario de La Santa Creu I Sant Pau, Barcelona, Spain. ⁵¹ Departments of Medicine and Anesthesia, Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA, USA. ⁵² Regional Intensive Care Unit, Royal Victoria Hospital, Belfast Health and Social Care Trust, Belfast, UK. ⁵³ Département de Médecine Intensive Réanimation, CHU d'Angers, Université d'Angers, Angers, France. ⁵⁴ University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. ⁵⁵ Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado, School of Medicine, Aurora, CO, USA. ⁵⁶ Interdepartmental Division of Critical Care Medicine, Sinai Health System, University of Toronto, Toronto, Canada. ⁵⁷ Department of Anesthesiology, Critical Care and Pain, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India. ⁵⁸ Division of Pulmonary and Critical Care Medicine, Montefiore Medical Center, Bronx, New York, NY, USA. ⁵⁹ Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, NY, USA. ⁶⁰ Bastia General Hospital Intensive Care Unit, Bastia, France. ⁶¹ Aix-Marseille University, Faculté de Médecine, Marseille, France. ⁶² Section of Pulmonary and Critical Care, Department of Medicine, University of Chicago, Chicago, IL, USA. ⁶³ Anesthesia and Intensive Care Medicine, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. ⁶⁴ Department of Intensive Care, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. ⁶⁵ Adult Intensive Care Unit, University Hospital and University of Lausanne, Lausanne, Switzerland. ⁶⁶ Jiangsu Provincial Key Laboratory of Critical Care Medicine, Department of Critical Care Medicine, Zhongda Hospital, Southeast University, Nanjing 210009, China. ⁶⁷ Alma Mater Studiorum - Università di Bologna, Bologna, Italy. ⁶⁸ Anesthesia and Intensive Care Medicine, IRCCS Policlinico di Sant'Orsola, Bologna, Italy. ⁶⁹ Division of Pulmonary, Critical Care and Sleep Medicine, Beth Israel Deaconess Medical Center and Harvard

Medical School, Boston, MA, USA. ⁷⁰ Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Vermont Larner College of Medicine, Burlington, VT, USA. ⁷¹ Department of Medicine, University of Cambridge Medical School, Cambridge, UK. ⁷² Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. ⁷³ University of São Paulo Medical School, São Paulo, Brazil. ⁷⁴ Hospital Israelita Albert Einstein, São Paulo, Brazil. ⁷⁵ CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain. ⁷⁶ Research Unit, Hospital Universitario Dr. Negrin, Las Palmas de Gran Canaria, Spain. ⁷⁷ Departments of Medicine and Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA. ⁷⁸ Department of Anesthesiology and Intensive Care Medicine (CCM CVK), Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany. ⁷⁹ Academic Research Organization, Albert Einstein Hospital, São Paulo, Brazil. ⁸⁰ Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada. ⁸¹ Médecine Intensive et Réanimation, APHP, Hôpital Saint-Louis, Paris Cité University, Paris, France. ⁸² Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. ⁸³ Department of Anesthesia and Intensive Care Medicine, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

Acknowledgments

We acknowledge the following patients and family representatives who contributed to the formulation of the PICO questions, the outcomes and the research gaps: Daniel Bertin (Switzerland), Phyllis Kay (USA), Eileen Rubin (USA), Sylvie Debigare (Canada), Kai Hughes (UK), Callum Ross (UK), Michael Bainbridge (UK), Pijush K. Roy (India). We are grateful to Guy Francois and the ESICM Research Office for their invaluable and continuous support. We thank Luigi Vivona and Amedeo Guzzardella for their technical assistance.

Funding

This work was supported by the European Society of Intensive Care Medicine.

Data availability

Not applicable.

Declarations

Conflicts of interest

GG received funding from Fischer&Paykel, MSD, Pfizer, and received fees from Getinge, Draeger Medical, Cook, MundiPharma, Fischer&Paykel, Pfizer. CSC received funding from National Institute of Health, Roche Genen Tech, Quantum Leap Health Care Collaborative and received fees from Cellenkos, Vasomune, NGM Bio, Gen1e Life Sciences. LC received fees from Draeger Medical, Hamilton, Medtronic. MA received funding from GE, Toray and received fees from Fischer&Paykel, Menarini, Pfizer. YMA is a Board member of International Severe Acute Respiratory and emerging Infection Consortium (ISARIC); is Co-Chair of International Study Steering Committee of O2CoV2 Study of World Health Organization and is PI of Helmet-COVID trial. JRB received funding from National Institute of Health, Quantum Leap Health Care Collaborative, Sedana Medical and received fees from Biomark Pharmaceuticals. GB received royalties from Flowmeter Spa and received fees from Flowmeter Spa, Draeger Medical, Getinge. LDJB received funding from Amsterdam UMC, Longfonds, European Respiratory Society, Innovative Medicine Initiative, Santhera, ZonMW, and received fees from AstraZeneca, Bayer, Novartis, Santhera, Sobi, Scailyte. LB received funding from Draeger Medical, Medtronic, Stimit, Vitalair and received fees from Fischer&Paykel and received equipments from Fischer&Paykel, Sentec. DB is Extracorporeal Life Support Organization President-elect and member board of directors and Chair Executive Committee of ECMONet. He is in the Data Safety Monitoring Board of ECMO-Rehab Study, was in the Advisory Boards for Livanova, Abiomed, Xenios, Medtronic, Inspira, Cellenkos and received funding from Livanova and received fees from Livanova, Abiomed, Xenios, Inspira, Medtronic, Cellenkos. KEAB is President of Canadian Critical Care Society, Past-Chair of Women in Critical Care of the American Thoracic Society and ex-officio member of Canadian Critical Care Trials Group Executive; she received fees from Fischer&Paykel. AC received fees from Getinge, Baxter, Fresenius. AD received funding from Philips, French Ministry of Health, Respinor, Lungpacer, Assistance publique – Hôpitaux de Paris, and received fees from Lungpacer, Respinor, Lowenstein, Tribunal administrative de Cergy, Liberate Medical,

Fischer&Paykel, Getinge, Agence Européenne Informatique, Astra, Baxter, Mindray. SE is member of American Society of Anesthesiology (Data Use Committee) and member of American Society of Anesthesiology (Perioperative Resuscitation and Life Support Committee); she is Data Safety Monitoring Board for the COVID-High Trial; she received fees from Oridion, Zoll, Medtronic, Fischer&Paykel and received equipments from Medtronic, Diasorin, Eli-Lilly, Eisai. EF received fees from Alung Technologies, Baxter, Inspira, Vasomune, Aerogen, GE. NDF is in the Advisory Board of NIH, MHRC Australia, Sedana Medical; he received funding from CIHR, received fees from Xenios. J-PF received funding from Fischer&Paykel, and received fees from Fischer&Paykel, SOS Oxygène. LG received funding from GE, Estor, and received fees from SIDAM, Grifols, Advitos, Apheretica, Estor, GE. MSH is the Committee of Canadian Critical Care Trials Group and in the Committee of Women in Critical Care of the American Thoracic Society; she received funding from Canadian Institute of Health Research and received support for travel from ESICM, ISICEM. CH leads the National ECMO Registry in Australia (EXCEL Registry) and sits in International ECMO Network Executive and Scientific Committee and is member of Research Committee for ELSO; she received funding from National Health and Medical Research Council, Medical Research Future Fund, AND received support for travel from Fischer&Paykel. CLH is in the Advisory Board of Quantum Health and received funding from National Institute of Health, American Lung Association. SJ received fees from Fischer&Paykel, Draeger Medical, Medtronic, Mindray, Baxter, Fresenius. CK is the Governmental Commission COVID-19 and Hospital Restructuring; he is in the Advisory Board of Bayer and Xenios; he received fees from Bayer, Xenios. AK received funding from Wellcome Trust, and received fees from Clinton Health Access Initiative; received equipments from Fischer&Paykel, and received support for travel from ESICM. JGL received funding from Science Foundation Ireland, Health Research Board Ireland, and received fees from Baxter. MAM received funding from National Institute of Health, Department of Defense, Roche-Genentech, and received fees from Novartis, Gilead Pharmaceuticals, Johnson and Johnson Pharmaceuticals, Cellenkos. DFMA is in the Data Safety Monitoring Board of Vlr Biotechnology Inc and of Faron Pharmaceuticals; he is Co-director of Research for the Intensive Care Society and is Director of EME Program of MR-NIHR; he received funding from NIHR, Wellcome Trust, Innovate UK, MRC, Northern Ireland HSC R&D Division, Randox, Novavax, and received royalties from Queen's University Belfast; he received fees from Bayer, GlaxoSmithKline, Boehringer Ingelheim, Novartis, Eli-Lilly, Sobi. AM is Past- President of the Franch Society of Intensive Care; he received funding from Air Liquide Medical Systems, Fischer&Paykel, and received fees from Bayer, Air Liquide Medical Systems, Fischer&Paykel, Getinge, Covidien, Draeger Medical. NJM is in the Data Safety Monitoring Board of Caviards and NIH Spiromics and Source Studies; he received funding from National Institute of Health, Quantum Leap Health Care Collaborative, and received fees from Endpoint Health Inc, NYU Langone Medical Center, and received support for travel from Intensive Care Society. MM is in the Advisory Board of an NIH Sponsored Trial, and received funding from National Institute of Health. LM was in the Ontario COVID-19 Science Advisory Table, is in the American Thoracic Society Mechanical Ventilation Guidelines Committee and in the ESICM Guidelines Committee; she is Section Editor of Intensive Care Medicine; she received funding from Leukemia and Lymphoma Society of Canada, H Barrie Fairley Scholarship. SNM is President Elect of Indian Society of Intensive Care Medicine; is Chair of Intensive Care Section of WFSA; she is member of the ESICM fluid Guidelines Committee. MNG is member of Data Safety Monitoring Board of Regeneration and EMORY; she is Chair of ATS Critical Care Assembly; she received funding from NHLBI, CDC, and received fees from New York Medical College, and received support for travel from ATS. LP is Data Safety Monitoring Board of SESAR; he received fees from Air Liquide Medical Systems, and received support for travel from Lowenstein. BKP received funding from National Institute of Health, Walder Foundation and University of Chicago and received fees from Merk, CHEST Foundation, Subpoena. AP is in Advisory Board of MEGA-ROX and UK-ROX Trails; he received funding from Novo Nordisc Foundation SYGEFORSIKRINGEN Pfizer, and received fees from Novartis. LP received fees from Lowenstein, Lungpacer, Getinge, Hamilton, Fischer&Paykel, GE, Air Liquide Medical Systems, and received support for travel from Getinge, Hamilton, Fischer&Paykel, GE, Air Liquide Medical Systems, and received equipments from Draeger Medical, Getinge. ER received funding from Wellcome Trust, and received equipments from Fischer&Paykel. ASS is Chair of Scientific Committee of ECMONet and he participated on DSMB for Gala Therapeutics; he received fees from Altimmune, Apeiron, Baxter, Cellenkos, Constant Therapeutics, Diffusion Pharmaceuticals, Edesa, Exvstat, Faron, GSK,

Krypton, SafeBVM, SaNOtize, Stimit, Thornhill Scientific, and received equipments from Thornhill Scientific. RDS was member of ATS Board of directors and is member of DSMBs of RCTs in North America and received funding from National Institute of Health, and received support for travel from National Institute of Health, ATS. CS received funding from NIHR, Wellcome Trust, UK Research and Innovation and received fees from GlaxoSmithKline, Abbvie, RocheSanofi-Pasteur. TBT received funding from Department of Defense, National Heart, Lung and Blood Institute and received fees from Bayer, Novartis, Genentech. CSVB is Scientific Director of Brazilian Association of Critical Care Medicine. JV received funding from Instituto de Salud Carlos III, Madrid, Spain (CB06/06/1088, PI19/00141), The European Regional Development Funds, and Fundación Canaria Instituto de Investigación Sanitaria de Canarias, Spain (PIFIISC21-36). LBW is the Chair of the American Thoracic Society Awards Committee and is in the DSMB of CHILL Study and SIGNET Study; he received funding from National Institute of Health, Genentech, Boehringer Ingelheim and received fees from Santhera, Global Blood Therapeutics, Boehringer Ingelheim, Merck, Citius, Foresee Pharmaceuticals. BW is member of ESICM NEXT Committee; he received fees from Orion Pharma LTD, Dr. F. Koehler Chemie and received support for travel from Teladoc Health. FGZ received fees from Bactiguard. EA received funding from MSD, GE, Alexion, Pfizer, received fees from Pfizer, Alexion, Mindray, Sanofi and received equipments from Pfizer. The remaining Authors have disclosed that they do not have any potential conflicts of interest.

Open Access

This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 12 January 2023 Accepted: 24 March 2023

Published: 16 June 2023

References

1. Ferguson ND, Fan E, Camporota L et al (2012) The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material. *Intensive Care Med* 38:1573–1582. <https://doi.org/10.1007/s00134-012-2682-1>
2. Ashbaugh D, Bigelow DB, Petty T, Levine B (1967) Acute respiratory distress in adults. *The Lancet* 290:319–323. [https://doi.org/10.1016/S0140-6736\(67\)90168-7](https://doi.org/10.1016/S0140-6736(67)90168-7)
3. Definition Task Force ARDS, Ranieri VM, Rubenfeld GD et al (2012) Acute respiratory distress syndrome: the Berlin Definition. *JAMA* 307:2526–2533. <https://doi.org/10.1001/jama.2012.5669>
4. Bellani G, Pham T, Laffey J et al (2016) Incidence of acute respiratory distress syndrome-reply. *JAMA* 316:347. <https://doi.org/10.1001/jama.2016.6471>
5. Tonetti T, Vasques F, Rapetti F et al (2017) Driving pressure and mechanical power: new targets for VILI prevention. *Ann Transl Med* 5:286. <https://doi.org/10.21037/atm.2017.07.08>
6. Gattinoni L, Carlesso E, Caironi P (2012) Stress and strain within the lung. *Curr Opin Crit Care* 18:42–47. <https://doi.org/10.1097/MCC.0b013e32834f17d9>
7. Gattinoni L, Pesenti A (2005) The concept of "baby lung." *Intensive Care Med* 31:776–784. <https://doi.org/10.1007/s00134-005-2627-z>

8. Guérin C, Albert RK, Beitler J et al (2020) Prone position in ARDS patients: why, when, how and for whom. *Intensive Care Med* 46:2385–2396. <https://doi.org/10.1007/s00134-020-06306-w>
9. Guérin C, Reignier J, Richard J-C et al (2013) Prone positioning in severe acute respiratory distress syndrome. *N Engl J Med* 368:2159–2168. <https://doi.org/10.1056/NEJMoa1214103>
10. Gattinoni L, Carlesso E, Taccone P et al (2010) Prone positioning improves survival in severe ARDS: a pathophysiologic review and individual patient meta-analysis. *Minerva Anestesiol* 76:448–454
11. Brochard L, Slutsky A, Pesenti A (2017) Mechanical ventilation to minimize progression of lung injury in acute respiratory failure. *Am J Respir Crit Care Med* 195:438–442. <https://doi.org/10.1164/rccm.201605-1081CP>
12. Combes A, Bréchet N, Luyt C-E, Schmidt M (2018) Indications for extracorporeal support: why do we need the results of the EOLIA trial? *Med Klin Intensivmed Notfmed* 113:21–25. <https://doi.org/10.1007/s00063-017-0371-0>
13. Fan E, Del Sorbo L, Goligher EC et al (2017) An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of critical care medicine clinical practice guideline: mechanical ventilation in adult patients with acute respiratory distress syndrome. *Am J Respir Crit Care Med* 195:1253–1263. <https://doi.org/10.1164/rccm.201703-0548ST>
14. Murray JF, Matthay MA, Luce JM, Flick MR (1988) An expanded definition of the adult respiratory distress syndrome. *Am Rev Respir Dis* 138:720–723. <https://doi.org/10.1164/ajrccm/138.3.720>
15. Bernard GR, Artigas A, Brigham KL et al (1994) Report of the American-European consensus conference on ARDS: definitions, mechanisms, relevant outcomes and clinical trial coordination. The Consensus Committee. *Intensive Care Med* 20:225–232. <https://doi.org/10.1007/BF01704707>
16. Riviello ED, Kiviri W, Twagirumugabe T et al (2016) Hospital incidence and outcomes of the acute respiratory distress syndrome using the Kigali modification of the berlin definition. *Am J Respir Crit Care Med* 193:52–59. <https://doi.org/10.1164/rccm.201503-0584OC>
17. Matthay MA, Thompson BT, Ware LB (2021) The Berlin definition of acute respiratory distress syndrome: should patients receiving high-flow nasal oxygen be included? *Lancet Respir Med* 9:933–936. [https://doi.org/10.1016/S2213-2600\(21\)00105-3](https://doi.org/10.1016/S2213-2600(21)00105-3)
18. Ranieri VM, Tonetti T, Navalesi P et al (2022) High-flow nasal oxygen for severe hypoxemia: oxygenation response and outcome in patients with COVID-19. *Am J Respir Crit Care Med* 205:431–439. <https://doi.org/10.1164/rccm.202109-2163OC>
19. Rice TW, Wheeler AP, Bernard GR et al (2007) Comparison of the SpO₂/FIO₂ ratio and the PaO₂/FIO₂ ratio in patients with acute lung injury or ARDS. *Chest* 132:410–417. <https://doi.org/10.1378/chest.07-0617>
20. Brown SM, Grissom CK, Moss M et al (2016) Nonlinear imputation of Pao₂/Fio₂ from Spo₂/Fio₂ among patients with acute respiratory distress syndrome. *Chest* 150:307–313. <https://doi.org/10.1016/j.chest.2016.01.003>
21. Moss M, Ulysse CA, Angus DC, Heart N, Lung, and Blood Institute PETAL Clinical Trials Network (2019) early neuromuscular blockade in the acute respiratory distress syndrome. *Reply N Engl J Med* 381:787–788. <https://doi.org/10.1056/NEJMc1908874>
22. Wick KD, Matthay MA, Ware LB (2022) Pulse oximetry for the diagnosis and management of acute respiratory distress syndrome. *Lancet Respir Med* 10:1086–1098. [https://doi.org/10.1016/S2213-2600\(22\)00058-3](https://doi.org/10.1016/S2213-2600(22)00058-3)
23. Meade MO, Cook RJ, Guyatt GH et al (2000) Interobserver variation in interpreting chest radiographs for the diagnosis of acute respiratory distress syndrome. *Am J Respir Crit Care Med* 161:85–90. <https://doi.org/10.1164/ajrccm.161.1.9809003>
24. Rubenfeld GD, Caldwell E, Granton J et al (1999) Interobserver variability in applying a radiographic definition for ARDS. *Chest* 116:1347–1353. <https://doi.org/10.1378/chest.116.5.1347>
25. Goddard SL, Rubenfeld GD, Manoharan V et al (2018) The randomized educational acute respiratory distress syndrome diagnosis study: a trial to improve the radiographic diagnosis of acute respiratory distress syndrome. *Crit Care Med* 46:743–748. <https://doi.org/10.1097/CCM.0000000000003000>
26. Khemani RG, Smith LS, Zimmerman JJ et al (2015) Pediatric acute respiratory distress syndrome: definition, incidence, and epidemiology: proceedings from the Pediatric Acute Lung Injury Consensus Conference. *Pediatr Crit Care Med* 16:S23–40. <https://doi.org/10.1097/PCC.0000000000000432>
27. Schenck EJ, Oromendia C, Torres LK et al (2019) Rapidly improving ARDS in therapeutic randomized controlled trials. *Chest* 155:474–482. <https://doi.org/10.1016/j.chest.2018.09.031>
28. Villar J, Kacmarek RM, Pérez-Méndez L, Aguirre-Jaime A (2006) A high positive end-expiratory pressure, low tidal volume ventilatory strategy improves outcome in persistent acute respiratory distress syndrome: a randomized, controlled trial. *Crit Care Med* 34:1311–1318. <https://doi.org/10.1097/01.CCM.0000215598.84885.01>
29. Villar J, Pérez-Méndez L, López J et al (2007) An early PEEP/FIO₂ trial identifies different degrees of lung injury in patients with acute respiratory distress syndrome. *Am J Respir Crit Care Med* 176:795–804. <https://doi.org/10.1164/rccm.200610-1534OC>
30. Ranieri VM, Rubenfeld G, Slutsky AS (2022) Rethinking ARDS after COVID-19. If a “better” definition is the answer, What is the question? *Am J Respir Crit Care Med*. <https://doi.org/10.1164/rccm.202206-1048CP>
31. Calfee CS, Delucchi K, Parsons PE et al (2014) Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. *Lancet Respir Med* 2:611–620. [https://doi.org/10.1016/S2213-2600\(14\)70097-9](https://doi.org/10.1016/S2213-2600(14)70097-9)
32. Mrozek S, Jabaudon M, Jaber S et al (2016) Elevated plasma levels of sRAGE are associated with nonfocal CT-based lung imaging in patients with ARDS: a prospective multicenter study. *Chest* 150:998–1007. <https://doi.org/10.1016/j.chest.2016.03.016>
33. Famous KR, Delucchi K, Ware LB et al (2017) Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. *Am J Respir Crit Care Med* 195:331–338. <https://doi.org/10.1164/rccm.201603-0645OC>
34. Bos LD, Schouten LR, van Vught LA et al (2017) Identification and validation of distinct biological phenotypes in patients with acute respiratory distress syndrome by cluster analysis. *Thorax* 72:876–883. <https://doi.org/10.1136/thoraxjnl-2016-209719>
35. Calfee CS, Delucchi KL, Sinha P et al (2018) ARDS subphenotypes and differential response to simvastatin: secondary analysis of a randomized controlled trial. *Lancet Respir Med* 6:691–698. [https://doi.org/10.1016/S2213-2600\(18\)30177-2](https://doi.org/10.1016/S2213-2600(18)30177-2)
36. Sinha P, Delucchi KL, Thompson BT et al (2018) Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study. *Intensive Care Med* 44:1859–1869. <https://doi.org/10.1007/s00134-018-5378-3>
37. Delucchi K, Famous KR, Ware LB et al (2018) Stability of ARDS subphenotypes over time in two randomised controlled trials. *Thorax* 73:439–445. <https://doi.org/10.1136/thoraxjnl-2017-211090>
38. Constantin J-M, Jabaudon M, Lefrant J-Y et al (2019) Personalised mechanical ventilation tailored to lung morphology versus low positive end-expiratory pressure for patients with acute respiratory distress syndrome in France (the LIVE study): a multicentre, single-blind, randomised controlled trial. *Lancet Respir Med* 7:870–880. [https://doi.org/10.1016/S2213-2600\(19\)30138-9](https://doi.org/10.1016/S2213-2600(19)30138-9)
39. Bos LDJ, Scicluna BP, Ong DSY et al (2019) Understanding heterogeneity in biologic phenotypes of acute respiratory distress syndrome by leukocyte expression profiles. *Am J Respir Crit Care Med* 200:42–50. <https://doi.org/10.1164/rccm.201809-1808OC>
40. Sinha P, Delucchi KL, McAuley DF et al (2020) Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials. *Lancet Respir Med* 8:247–257. [https://doi.org/10.1016/S2213-2600\(19\)30369-8](https://doi.org/10.1016/S2213-2600(19)30369-8)
41. Sinha P, Calfee CS, Cherian S et al (2020) Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study. *Lancet Respir Med* 8:1209–1218. [https://doi.org/10.1016/S2213-2600\(20\)30366-0](https://doi.org/10.1016/S2213-2600(20)30366-0)
42. Sinha P, Churpek MM, Calfee CS (2020) Machine learning classifier models can identify acute respiratory distress syndrome phenotypes using readily available clinical data. *Am J Respir Crit Care Med* 202:996–1004. <https://doi.org/10.1164/rccm.202002-0347OC>
43. Zhang S, Lu Z, Wu Z et al (2020) Determination of a “Specific Population Who Could Benefit From Rosuvastatin”: a secondary analysis of a

- randomized controlled trial to uncover the novel value of rosuvastatin for the precise treatment of ARDS. *Front Med (Lausanne)* 7:598621. <https://doi.org/10.3389/fmed.2020.598621>
44. Wendel Garcia PD, Caccioppola A, Coppola S et al (2021) Latent class analysis to predict intensive care outcomes in Acute Respiratory Distress Syndrome: a proposal of two pulmonary phenotypes. *Crit Care* 25:154. <https://doi.org/10.1186/s13054-021-03578-6>
 45. Bos LDJ, Sjoding M, Sinha P et al (2021) Longitudinal respiratory subphenotypes in patients with COVID-19-related acute respiratory distress syndrome: results from three observational cohorts. *Lancet Respir Med* 9:1377–1386. [https://doi.org/10.1016/S2213-2600\(21\)00365-9](https://doi.org/10.1016/S2213-2600(21)00365-9)
 46. Sinha P, Furfaro D, Cummings MJ et al (2021) Latent class analysis reveals COVID-19-related acute respiratory distress syndrome subgroups with differential responses to corticosteroids. *Am J Respir Crit Care Med* 204:1274–1285. <https://doi.org/10.1164/rccm.202105-1302OC>
 47. Liu X, Jiang Y, Xia X et al (2021) Identification of distinct clinical phenotypes of acute respiratory distress syndrome with differential responses to treatment. *Crit Care* 25:320. <https://doi.org/10.1186/s13054-021-03734-y>
 48. Vasquez CR, Gupta S, Miano TA et al (2021) Identification of distinct clinical subphenotypes in critically ill patients with COVID-19. *Chest* 160:929–943. <https://doi.org/10.1016/j.chest.2021.04.062>
 49. Ranjeva S, Pinciroli R, Hodell E et al (2021) Identifying clinical and biochemical phenotypes in acute respiratory distress syndrome secondary to coronavirus disease-2019. *EClinicalMedicine* 34:100829. <https://doi.org/10.1016/j.eclinm.2021.100829>
 50. Lascarrou J-B, Gaultier A, Soumagne T et al (2021) Identifying clinical phenotypes in moderate to severe acute respiratory distress syndrome related to COVID-19: the COVADIS study. *Front Med (Lausanne)* 8:632933. <https://doi.org/10.3389/fmed.2021.632933>
 51. Xing C-Y, Gong W-B, Yang Y-N et al (2021) ARDS patients exhibiting a "Hyperinflammatory Anasarca" phenotype could benefit from a conservative fluid management strategy. *Front Med (Lausanne)* 8:727910. <https://doi.org/10.3389/fmed.2021.727910>
 52. Sinha P, Delucchi KL, Chen Y et al (2022) Latent class analysis-derived subphenotypes are generalisable to observational cohorts of acute respiratory distress syndrome: a prospective study. *Thorax* 77:13–21. <https://doi.org/10.1136/thoraxjnl-2021-217158>
 53. Hashem MD, Hopkins RO, Colantuoni E et al (2022) Six-month and 12-month patient outcomes based on inflammatory subphenotypes in sepsis-associated ARDS: secondary analysis of SAILS-ALTOS trial. *Thorax* 77:22–30. <https://doi.org/10.1136/thoraxjnl-2020-216613>
 54. Maddali MV, Churpek M, Pham T et al (2022) Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective analysis. *Lancet Respir Med* 10:367–377. [https://doi.org/10.1016/S2213-2600\(21\)00461-6](https://doi.org/10.1016/S2213-2600(21)00461-6)
 55. Duggal A, Kast R, Van Ark E et al (2022) Identification of acute respiratory distress syndrome subphenotypes de novo using routine clinical data: a retrospective analysis of ARDS clinical trials. *BMJ Open* 12:e053297. <https://doi.org/10.1136/bmjopen-2021-053297>
 56. Gattinoni L, Caironi P, Cressoni M et al (2006) Lung recruitment in patients with the acute respiratory distress syndrome. *N Engl J Med* 354:1775–1786. <https://doi.org/10.1056/NEJMoa052052>
 57. Nishimura M (2015) High-flow nasal cannula oxygen therapy in adults. *J Intensive Care* 3:15. <https://doi.org/10.1186/s40560-015-0084-5>
 58. Parke R, McGuinness S, Eccleston M (2009) Nasal high-flow therapy delivers low level positive airway pressure. *Br J Anaesth* 103:886–890. <https://doi.org/10.1093/bja/aep280>
 59. Frat J-P, Thille AW, Mercat A et al (2015) High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. *N Engl J Med* 372:2185–2196. <https://doi.org/10.1056/NEJMoa1503326>
 60. Perkins GD, Ji C, Connolly BA et al (2022) Effect of noninvasive respiratory strategies on intubation or mortality among patients with acute hypoxemic respiratory failure and COVID-19: the RECOVERY-RS randomized clinical trial. *JAMA* 327:546–558. <https://doi.org/10.1001/jama.2022.0028>
 61. Azoulay E, Lemiale V, Mokart D et al (2018) Effect of high-flow nasal oxygen vs standard oxygen on 28-day mortality in immunocompromised patients with acute respiratory failure: the HIGH randomized clinical trial. *JAMA* 320:2099–2107. <https://doi.org/10.1001/jama.2018.14282>
 62. Ospina-Tascón GA, Calderón-Tapia LE, García AF et al (2021) Effect of high-flow oxygen therapy vs conventional oxygen therapy on invasive mechanical ventilation and clinical recovery in patients with severe COVID-19: a randomized clinical trial. *JAMA* 326:2161–2171. <https://doi.org/10.1001/jama.2021.20714>
 63. Frat J-P, Quenot J-P, Badier J et al (2022) Effect of high-flow nasal cannula oxygen vs standard oxygen therapy on mortality in patients with respiratory failure due to COVID-19: the SOHO-COVID randomized clinical trial. *JAMA* 328:1212–1222. <https://doi.org/10.1001/jama.2022.15613>
 64. Alptekinoglu Mendil N, Temel Ş, Yüksel RC et al (2021) The use of high-flow nasal oxygen vs. standard oxygen therapy in hematological malignancy patients with acute respiratory failure in hematology wards. *Turk J Med Sci* 51:1756–1763. <https://doi.org/10.3906/sag-2007-228>
 65. Bouadma L, Mekontso-Dessap A, Burdet C et al (2022) High-dose dexamethasone and oxygen support strategies in intensive care unit patients with severe COVID-19 acute hypoxemic respiratory failure: the COVIDICUS randomized clinical trial. *JAMA Intern Med* 182:906–916. <https://doi.org/10.1001/jamainternmed.2022.2168>
 66. Prakash J, Bhattacharya PK, Yadav AK et al (2021) ROX index as a good predictor of high flow nasal cannula failure in COVID-19 patients with acute hypoxemic respiratory failure: A systematic review and meta-analysis. *J Crit Care* 66:102–108. <https://doi.org/10.1016/j.jccr.2021.08.012>
 67. Azoulay E, Pickkers P, Soares M et al (2017) Acute hypoxemic respiratory failure in immunocompromised patients: the Efrain multinational prospective cohort study. *Intensive Care Med* 43:1808–1819. <https://doi.org/10.1007/s00134-017-4947-1>
 68. Rochweg B, Brochard L, Elliott MW et al (2017) Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. *Eur Respir J* 50:1602426. <https://doi.org/10.1183/13993003.02426-2016>
 69. Wang D, Hu B, Hu C et al (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA* 323:1061–1069. <https://doi.org/10.1001/jama.2020.1585>
 70. Alhazzani W, Møller MH, Arabi YM et al (2020) Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). *Intensive Care Med* 46:854–887. <https://doi.org/10.1007/s00134-020-06022-5>
 71. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at <https://www.covid19treatmentguidelines.nih.gov/>
 72. Alraddadi BM, Qushmaq I, Al-Hameed FM et al (2019) Noninvasive ventilation in critically ill patients with the Middle East respiratory syndrome. *Influenza Other Respir Viruses* 13:382–390. <https://doi.org/10.1111/irv.12635>
 73. Tran K, Cimon K, Severn M et al (2012) Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review. *PLoS ONE* 7:e35797. <https://doi.org/10.1371/journal.pone.0035797>
 74. Nair PR, Haritha D, Behera S et al (2021) Comparison of high-flow nasal cannula and noninvasive ventilation in acute hypoxemic respiratory failure due to severe COVID-19 pneumonia. *Respir Care* 66:1824–1830. <https://doi.org/10.4187/respcare.09130>
 75. Grieco DL, Menga LS, Cesarano M et al (2021) Effect of helmet noninvasive ventilation vs high-flow nasal oxygen on days free of respiratory support in patients with COVID-19 and moderate to severe hypoxemic respiratory failure: the HENIVOT randomized clinical trial. *JAMA* 325:1731–1743. <https://doi.org/10.1001/jama.2021.4682>
 76. Coudroy R, Frat J-P, Ehrmann S et al (2022) High-flow nasal oxygen alone or alternating with non-invasive ventilation in critically ill immunocompromised patients with acute respiratory failure: a randomised controlled trial. *Lancet Respir Med* 10:641–649. [https://doi.org/10.1016/S2213-2600\(22\)00096-0](https://doi.org/10.1016/S2213-2600(22)00096-0)
 77. Munshi L, Mancebo J, Brochard LJ (2022) Noninvasive respiratory support for adults with acute respiratory failure. *N Engl J Med* 387:1688–1698. <https://doi.org/10.1056/NEJMra2204556>
 78. Brambilla AM, Aliberti S, Prina E et al (2014) Helmet CPAP vs. oxygen therapy in severe hypoxemic respiratory failure due to

- pneumonia. *Intensive Care Med* 40:942–949. <https://doi.org/10.1007/s00134-014-3325-5>
79. Squadrone V, Massaia M, Bruno B et al (2010) Early CPAP prevents evolution of acute lung injury in patients with hematologic malignancy. *Intensive Care Med* 36:1666–1674. <https://doi.org/10.1007/s00134-010-1934-1>
 80. Cosentini R, Brambilla AM, Aliberti S et al (2010) Helmet continuous positive airway pressure vs oxygen therapy to improve oxygenation in community-acquired pneumonia: a randomized, controlled trial. *Chest* 138:114–120. <https://doi.org/10.1378/chest.09-2290>
 81. Lemiale V, Mokart D, Resche-Rigon M et al (2015) Effect of noninvasive ventilation vs oxygen therapy on mortality among immunocompromised patients with acute respiratory failure: a randomized clinical trial. *JAMA* 314:1711–1719. <https://doi.org/10.1001/jama.2015.12402>
 82. He H, Sun B, Liang L et al (2019) A multicenter RCT of noninvasive ventilation in pneumonia-induced early mild acute respiratory distress syndrome. *Crit Care* 23:300. <https://doi.org/10.1186/s13054-019-2575-6>
 83. Zhan Q, Sun B, Liang L et al (2012) Early use of noninvasive positive pressure ventilation for acute lung injury: a multicenter randomized controlled trial. *Crit Care Med* 40:455–460. <https://doi.org/10.1097/CCM.0b013e318232d75e>
 84. Hillbert G, Gruson D, Vargas F et al (2001) Noninvasive ventilation in immunosuppressed patients with pulmonary infiltrates, fever, and acute respiratory failure. *N Engl J Med* 344:481–487. <https://doi.org/10.1056/NEJM200102153440703>
 85. Wermke M, Schiemanck S, Höffken G et al (2012) Respiratory failure in patients undergoing allogeneic hematopoietic SCT—a randomized trial on early non-invasive ventilation based on standard care hematology wards. *Bone Marrow Transplant* 47:574–580. <https://doi.org/10.1038/bmt.2011.160>
 86. Yoshida T, Amato MBP, Kavanagh BP, Fujino Y (2019) Impact of spontaneous breathing during mechanical ventilation in acute respiratory distress syndrome. *Curr Opin Crit Care* 25:192–198. <https://doi.org/10.1097/MCC.0000000000000597>
 87. Antonelli M, Conti G, Pelosi P et al (2002) New treatment of acute hypoxemic respiratory failure: noninvasive pressure support ventilation delivered by helmet—a pilot controlled trial. *Crit Care Med* 30:602–608. <https://doi.org/10.1097/00003246-200203000-00019>
 88. Antonelli M, Pennisi MA, Pelosi P et al (2004) Noninvasive positive pressure ventilation using a helmet in patients with acute exacerbation of chronic obstructive pulmonary disease: a feasibility study. *Anesthesiology* 100:16–24. <https://doi.org/10.1097/0000542-200401000-00007>
 89. Vargas F, Thille A, Lyazidi A et al (2009) Helmet with specific settings versus facemask for noninvasive ventilation. *Crit Care Med* 37:1921–1928. <https://doi.org/10.1097/CCM.0b013e31819ff993>
 90. Coppadoro A, Zago E, Pavan F et al (2021) The use of head helmets to deliver noninvasive ventilatory support: a comprehensive review of technical aspects and clinical findings. *Crit Care* 25:327. <https://doi.org/10.1186/s13054-021-03746-8>
 91. Patel BK, Wolfe KS, Pohlman AS et al (2016) Effect of noninvasive ventilation delivered by helmet vs face mask on the rate of endotracheal intubation in patients with acute respiratory distress syndrome: a randomized clinical trial. *JAMA* 315:2435–2441. <https://doi.org/10.1001/jama.2016.6338>
 92. Patel BK, Wolfe KS, MacKenzie E et al (2018) One year outcomes in patients with acute respiratory distress syndrome enrolled in a randomized clinical trial of helmet versus facemask noninvasive ventilation. *Crit Care Med* 46:1078–1084. <https://doi.org/10.1097/CCM.00000000000003124>
 93. Roubly JJ, Lherm T, Martin de Lassale E et al (1993) Histologic aspects of pulmonary barotrauma in critically ill patients with acute respiratory failure. *Intensive Care Med* 19:383–389. <https://doi.org/10.1007/BF01724877>
 94. Slutsky AS, Ranieri VM (2013) Ventilator-induced lung injury. *N Engl J Med* 369:2126–2136. <https://doi.org/10.1056/NEJMra1208707>
 95. Brochard L, Roudot-Thoraval F, Roupie E et al (1998) Tidal volume reduction for prevention of ventilator-induced lung injury in acute respiratory distress syndrome. The Multicenter Trial Group on Tidal Volume reduction in ARDS. *Am J Respir Crit Care Med* 158:1831–1838. <https://doi.org/10.1164/ajrccm.158.6.9801044>
 96. Amato MB, Barbas CS, Medeiros DM et al (1998) Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. *N Engl J Med* 338:347–354. <https://doi.org/10.1056/NEJM199802053380602>
 97. Stewart TE, Meade MO, Cook DJ et al (1998) Evaluation of a ventilation strategy to prevent barotrauma in patients at high risk for acute respiratory distress syndrome. Pressure- and Volume-Limited Ventilation Strategy Group. *N Engl J Med* 338:355–361. <https://doi.org/10.1056/NEJM199802053380603>
 98. Brower RG, Shanholtz CB, Fessler HE et al (1999) Prospective, randomized, controlled clinical trial comparing traditional versus reduced tidal volume ventilation in acute respiratory distress syndrome patients. *Crit Care Med* 27:1492–1498. <https://doi.org/10.1097/00003246-199908000-00015>
 99. Network ARDS, Brower RG, Matthay MA et al (2000) Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. *N Engl J Med* 342:1301–1308. <https://doi.org/10.1056/NEJM200005043421801>
 100. Orme J, Romney JS, Hopkins RO et al (2003) Pulmonary function and health-related quality of life in survivors of acute respiratory distress syndrome. *Am J Respir Crit Care Med* 167:690–694. <https://doi.org/10.1164/rccm.200206-542OC>
 101. Reddy MP, Subramaniam A, Chua C et al (2022) Respiratory system mechanics, gas exchange, and outcomes in mechanically ventilated patients with COVID-19-related acute respiratory distress syndrome: a systematic review and meta-analysis. *Lancet Respir Med*. [https://doi.org/10.1016/s2213-2600\(22\)00393-9](https://doi.org/10.1016/s2213-2600(22)00393-9)
 102. Costa ELV, Slutsky AS, Brochard LJ et al (2021) Ventilatory variables and mechanical power in patients with acute respiratory distress syndrome. *Am J Respir Crit Care Med* 204:303–311. <https://doi.org/10.1164/rccm.202009-3467OC>
 103. Matthay MA, Zemans RL, Zimmerman GA et al (2019) Acute respiratory distress syndrome. *Nat Rev Dis Primers*. <https://doi.org/10.1038/s41572-019-0069-0>
 104. Cressoni M, Cadringer P, Chiuazzini C et al (2014) Lung inhomogeneity in patients with acute respiratory distress syndrome. *Am J Respir Crit Care Med* 189:149–158. <https://doi.org/10.1164/rccm.201308-1567OC>
 105. Mertens M, Tabuchi A, Meissner S et al (2009) Alveolar dynamics in acute lung injury: heterogeneous distension rather than cyclic opening and collapse. *Crit Care Med* 37:2604–2611. <https://doi.org/10.1097/CCM.0b013e3181a5544d>
 106. Brower RG, Lanken PN, MacIntyre N et al (2004) Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. *N Engl J Med* 351:327–336. <https://doi.org/10.1056/NEJMoa032193>
 107. Meade MO, Cook DJ, Guyatt GH et al (2008) Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. *JAMA* 299:637–645. <https://doi.org/10.1001/jama.299.6.637>
 108. Mercat A, Richard J-CM, Vieille B et al (2008) Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. *JAMA* 299:646–655. <https://doi.org/10.1001/jama.299.6.646>
 109. Talmor D, Sarge T, Malhotra A et al (2008) Mechanical ventilation guided by esophageal pressure in acute lung injury. *N Engl J Med* 359:2095–2104. <https://doi.org/10.1056/NEJMoa0708638>
 110. Beitler JR, Sarge T, Banner-Goodspeed VM et al (2019) Effect of titrating positive end-expiratory pressure (PEEP) with an esophageal pressure-guided strategy vs an empirical high PEEP-FiO₂ strategy on death and days free from mechanical ventilation among patients with acute respiratory distress syndrome: a randomized clinical trial. *JAMA* 321:846–857. <https://doi.org/10.1001/jama.2019.0555>
 111. Pintado M-C, de Pablo R, Trascasa M et al (2013) Individualized PEEP setting in subjects with ARDS: a randomized controlled pilot study. *Respir Care* 58:1416–1423. <https://doi.org/10.4187/respcare.02068>
 112. Writing Group for the Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial (ART) Investigators, Cavalcanti AB, Suzumura EA et al (2017) Effect of lung recruitment and titrated positive end-expiratory pressure (PEEP) vs low PEEP on mortality in patients with

- acute respiratory distress syndrome: a randomized clinical trial. *JAMA* 318:1335–1345. <https://doi.org/10.1001/jama.2017.14171>
113. Briel M, Meade M, Mercat A et al (2010) Higher vs lower positive end-expiratory pressure in patients with acute lung injury and acute respiratory distress syndrome: systematic review and meta-analysis. *JAMA* 303:865–873. <https://doi.org/10.1001/jama.2010.218>
 114. Dianti J, Tisminetzky M, Ferreyro BL et al (2022) Association of positive end-expiratory pressure and lung recruitment selection strategies with mortality in acute respiratory distress syndrome: a systematic review and network meta-analysis. *Am J Respir Crit Care Med* 205:1300–1310. <https://doi.org/10.1164/rccm.202108-1972OC>
 115. Brower RG, Morris A, MacIntyre N et al (2003) Effects of recruitment maneuvers in patients with acute lung injury and acute respiratory distress syndrome ventilated with high positive end-expiratory pressure. *Crit Care Med* 31:2592–2597. <https://doi.org/10.1097/01.CCM.0000090001.91640.45>
 116. Crotti S, Mascheroni D, Caironi P et al (2001) Recruitment and derecruitment during acute respiratory failure: a clinical study. *Am J Respir Crit Care Med* 164:131–140. <https://doi.org/10.1164/ajrccm.164.1.2007011>
 117. Borges JB, Okamoto VN, Matos GFJ et al (2006) Reversibility of lung collapse and hypoxemia in early acute respiratory distress syndrome. *Am J Respir Crit Care Med* 174:268–278. <https://doi.org/10.1164/rccm.200506-976OC>
 118. Pulletz S, Adler A, Kott M et al (2012) Regional lung opening and closing pressures in patients with acute lung injury. *J Crit Care* 27:323.e11-323.e18. <https://doi.org/10.1016/j.jccr.2011.09.002>
 119. Fan E, Wilcox ME, Brower RG et al (2008) Recruitment maneuvers for acute lung injury: a systematic review. *Am J Respir Crit Care Med* 178:1156–1163. <https://doi.org/10.1164/rccm.200802-335OC>
 120. Gattinoni L, Pesenti A, Avalli L et al (1987) Pressure-volume curve of total respiratory system in acute respiratory failure. Computed tomographic scan study. *Am Rev Respir Dis* 136:730–736. <https://doi.org/10.1164/ajrccm/136.3.730>
 121. Malbouisson LM, Muller JC, Constantin JM et al (2001) Computed tomography assessment of positive end-expiratory pressure-induced alveolar recruitment in patients with acute respiratory distress syndrome. *Am J Respir Crit Care Med* 163:1444–1450. <https://doi.org/10.1164/ajrccm.163.6.2005001>
 122. Jonson B, Richard JC, Straus C et al (1999) Pressure-volume curves and compliance in acute lung injury: evidence of recruitment above the lower inflection point. *Am J Respir Crit Care Med* 159:1172–1178. <https://doi.org/10.1164/ajrccm.159.4.9801088>
 123. Bouhemad B, Brisson H, Le-Guen M et al (2011) Bedside ultrasound assessment of positive end-expiratory pressure-induced lung recruitment. *Am J Respir Crit Care Med* 183:341–347. <https://doi.org/10.1164/rccm.201003-0369OC>
 124. Chiumello D, Marino A, Brioni M et al (2016) Lung recruitment assessed by respiratory mechanics and computed tomography in patients with acute respiratory distress syndrome. What is the relationship? *Am J Respir Crit Care Med* 193:1254–1263. <https://doi.org/10.1164/rccm.201507-1413OC>
 125. Maggiore SM, Jonson B, Richard JC et al (2001) Alveolar derecruitment at decremental positive end-expiratory pressure levels in acute lung injury: comparison with the lower inflection point, oxygenation, and compliance. *Am J Respir Crit Care Med* 164:795–801. <https://doi.org/10.1164/ajrccm.164.5.2006071>
 126. Cressoni M, Chiumello D, Algieri I et al (2017) Opening pressures and atelectrauma in acute respiratory distress syndrome. *Intensive Care Med* 43:603–611. <https://doi.org/10.1007/s00134-017-4754-8>
 127. Pelosi P, Cadringer P, Bottino N et al (1999) Sigh in acute respiratory distress syndrome. *Am J Respir Crit Care Med* 159:872–880
 128. Hodgson CL, Tuxen DV, Davies AR et al (2011) A randomised controlled trial of an open lung strategy with staircase recruitment, titrated PEEP and targeted low airway pressures in patients with acute respiratory distress syndrome. *Crit Care* 15:R133. <https://doi.org/10.1186/cc10249>
 129. Hodgson CL, Cooper DJ, Arabi Y et al (2019) Maximal recruitment open lung ventilation in acute respiratory distress syndrome (PHARLAP): a phase II, multicenter randomized controlled clinical trial. *Am J Respir Crit Care Med* 200:1363–1372. <https://doi.org/10.1164/rccm.201901-0109OC>
 130. Kung S-C, Hung Y-L, Chen W-L et al (2019) Effects of stepwise lung recruitment maneuvers in patients with early acute respiratory distress syndrome: a prospective, randomized, controlled trial. *J Clin Med* 8:231. <https://doi.org/10.3390/jcm8020231>
 131. Chung F-T, Lee C-S, Lin S-M et al (2017) Alveolar recruitment maneuver attenuates extravascular lung water in acute respiratory distress syndrome. *Medicine* 96:e7627. <https://doi.org/10.1097/MD.00000000000007627>
 132. Lam NN, Hung TD, Hung DK (2019) Impact of “opening the lung” ventilatory strategy on burn patients with acute respiratory distress syndrome. *Burns* 45:1841–1847. <https://doi.org/10.1016/j.burns.2019.05.016>
 133. Kacmarek RM, Villar J, Sulemanji D et al (2016) Open lung approach for the acute respiratory distress syndrome: a pilot, randomized controlled trial. *Crit Care Med* 44:32–42. <https://doi.org/10.1097/CCM.00000000000001383>
 134. Xi X-M, Jiang L, Zhu B, RM group (2010) Clinical efficacy and safety of recruitment maneuver in patients with acute respiratory distress syndrome using low tidal volume ventilation: a multicenter randomized controlled clinical trial. *Chin Med J (Engl)* 123:3100–3105
 135. Nielsen J, Østergaard M, Kjaergaard J et al (2005) Lung recruitment maneuver depresses central hemodynamics in patients following cardiac surgery. *Intensive Care Med* 31:1189–1194. <https://doi.org/10.1007/s00134-005-2732-z>
 136. Marini JJ, Gattinoni L (2020) Time course of evolving ventilator-induced lung injury: the “shrinking baby lung.” *Crit Care Med* 48:1203–1209. <https://doi.org/10.1097/CCM.00000000000004416>
 137. Mauri T, Eronia N, Abbruzzese C et al (2015) Effects of sigh on regional lung strain and ventilation heterogeneity in acute respiratory failure patients undergoing assisted mechanical ventilation. *Crit Care Med* 43:1823–1831. <https://doi.org/10.1097/CCM.0000000000001083>
 138. Gattinoni L, Tognoni G, Pesenti A et al (2001) Effect of prone positioning on the survival of patients with acute respiratory failure. *N Engl J Med* 345:568–573. <https://doi.org/10.1056/NEJMoa010043>
 139. Guerin C, Gaillard S, Lemasson S et al (2004) Effects of systematic prone positioning in hypoxemic acute respiratory failure: a randomized controlled trial. *JAMA* 292:2379–2387. <https://doi.org/10.1001/jama.292.19.2379>
 140. Voggenreiter G, Aufmkolk M, Stiletto RJ et al (2005) Prone positioning improves oxygenation in post-traumatic lung injury—a prospective randomized trial. *J Trauma* 59:333–341. <https://doi.org/10.1097/01.ta.0000179952.95921.49>
 141. Chan M-C, Hsu J-Y, Liu H-H et al (2007) Effects of prone position on inflammatory markers in patients with ARDS due to community-acquired pneumonia. *J Formos Med Assoc* 106:708–716. [https://doi.org/10.1016/s0929-6646\(08\)60032-7](https://doi.org/10.1016/s0929-6646(08)60032-7)
 142. Fernandez R, Trenchs X, Klamburg J et al (2008) Prone positioning in acute respiratory distress syndrome: a multicenter randomized clinical trial. *Intensive Care Med* 34:1487–1491. <https://doi.org/10.1007/s00134-008-1119-3>
 143. Mancebo J, Fernández R, Blanch L et al (2006) A multicenter trial of prolonged prone ventilation in severe acute respiratory distress syndrome. *Am J Respir Crit Care Med* 173:1233–1239. <https://doi.org/10.1164/rccm.200503-353OC>
 144. Taccone P, Pesenti A, Latini R et al (2009) Prone positioning in patients with moderate and severe acute respiratory distress syndrome: a randomized controlled trial. *JAMA* 302:1977–1984. <https://doi.org/10.1001/jama.2009.1614>
 145. Poole D, Pisa A, Fumagalli R (2023) Prone position for acute respiratory distress syndrome and the hazards of meta-analysis. *Pulmonology*. <https://doi.org/10.1016/j.pulmoe.2022.12.005>
 146. Weatherald J, Parhar KKS, Duhailib ZA et al (2022) Efficacy of awake prone positioning in patients with covid-19 related hypoxemic respiratory failure: systematic review and meta-analysis of randomized trials. *BMJ* 379:e071966. <https://doi.org/10.1136/bmj-2022-071966>
 147. Ehrmann S, Li J, Ibarra-Estrada M et al (2021) Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial. *Lancet Respir Med* 9:1387–1395. [https://doi.org/10.1016/S2213-2600\(21\)00356-8](https://doi.org/10.1016/S2213-2600(21)00356-8)
 148. Rosén J, von Oelreich E, Fors D et al (2021) Awake prone positioning in patients with hypoxemic respiratory failure due to COVID-19: the

- PROFLO multicenter randomized clinical trial. *Crit Care* 25:209. <https://doi.org/10.1186/s13054-021-03602-9>
149. Alhazzani W, Parhar KKS, Weatherald J et al (2022) Effect of awake prone positioning on endotracheal intubation in patients with COVID-19 and acute respiratory failure: a randomized clinical trial. *JAMA* 327:2104–2113. <https://doi.org/10.1001/jama.2022.7993>
 150. Slutsky AS (2010) Neuromuscular blocking agents in ARDS. *N Engl J Med* 363:1176–1180. <https://doi.org/10.1056/NEJMe1007136>
 151. Price DR, Mikkelsen ME, Umscheid CA, Armstrong EJ (2016) Neuro-muscular blocking agents and neuromuscular dysfunction acquired in critical illness: a systematic review and meta-analysis. *Crit Care Med* 44:2070–2078. <https://doi.org/10.1097/CCM.0000000000001839>
 152. Barr J, Fraser GL, Puntillo K et al (2013) Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. *Crit Care Med* 41:263–306. <https://doi.org/10.1097/CCM.0b013e3182783b72>
 153. Papazian L, Forel J-M, Gacouin A et al (2010) Neuromuscular blockers in early acute respiratory distress syndrome. *N Engl J Med* 363:1107–1116. <https://doi.org/10.1056/NEJMoa1005372>
 154. Forel J-M, Roch A, Marin V et al (2006) Neuromuscular blocking agents decrease inflammatory response in patients presenting with acute respiratory distress syndrome. *Crit Care Med* 34:2749–2757. <https://doi.org/10.1097/01.CCM.0000239435.87433.0D>
 155. Gainnier M, Roch A, Forel J-M et al (2004) Effect of neuromuscular blocking agents on gas exchange in patients presenting with acute respiratory distress syndrome. *Crit Care Med* 32:113–119. <https://doi.org/10.1097/01.CCM.0000104114.72614.BC>
 156. Guervilly C, Bisbal M, Forel JM et al (2017) Effects of neuromuscular blockers on transpulmonary pressures in moderate to severe acute respiratory distress syndrome. *Intensive Care Med* 43:408–418. <https://doi.org/10.1007/s00134-016-4653-4>
 157. National Heart, Lung, and Blood Institute PETAL Clinical Trials Network, Moss M, Huang DT et al (2019) Early neuromuscular blockade in the acute respiratory distress syndrome. *N Engl J Med* 380:1997–2008. <https://doi.org/10.1056/NEJMoa1901686>
 158. Tsolaki V, Zakyntinos GE, Papadonta M-E et al (2022) Neuromuscular blockade in the pre- and COVID-19 ARDS patients. *J Pers Med* 12:1538. <https://doi.org/10.3390/jpm12091538>
 159. Schmidt M, Francheau G, Combes A (2019) Recent advances in venovenous extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. *Curr Opin Crit Care* 25:71–76. <https://doi.org/10.1097/MCC.0000000000000567>
 160. Barbaro RP, Odetola FO, Kidwell KM et al (2015) Association of hospital-level volume of extracorporeal membrane oxygenation cases and mortality. Analysis of the extracorporeal life support organization registry. *Am J Respir Crit Care Med* 191:894–901. <https://doi.org/10.1164/rccm.201409-1634OC>
 161. Peek GJ, Mugford M, Tiruvoipati R et al (2009) Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. *The Lancet* 374:1351–1363. [https://doi.org/10.1016/s0140-6736\(09\)61069-2](https://doi.org/10.1016/s0140-6736(09)61069-2)
 162. Combes A, Hajage D, Capellier G et al (2018) Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. *N Engl J Med* 378:1965–1975. <https://doi.org/10.1056/NEJMoa1800385>
 163. Goligher EC, Tomlinson G, Hajage D et al (2018) Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome and posterior probability of mortality benefit in a post hoc bayesian analysis of a randomized clinical trial. *JAMA* 320:2251–2259. <https://doi.org/10.1001/jama.2018.14276>
 164. Noah MA, Peek GJ, Finney SJ et al (2011) Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A(H1N1). *JAMA* 306:1659. <https://doi.org/10.1001/jama.2011.1471>
 165. Pham T, Combes A, Rozé H et al (2013) Extracorporeal membrane oxygenation for pandemic influenza A(H1N1)-induced acute respiratory distress syndrome: a cohort study and propensity-matched analysis. *Am J Respir Crit Care Med* 187:276–285. <https://doi.org/10.1164/rccm.201205-0815OC>
 166. Fang J, Li R, Chen Y et al (2021) Extracorporeal membrane oxygenation therapy for critically ill coronavirus disease 2019 patients in Wuhan, China: a retrospective multicenter cohort study. *Curr Med Sci* 41:1–13. <https://doi.org/10.1007/s11596-021-2311-8>
 167. Shaefi S, Brenner SK, Gupta S et al (2021) Extracorporeal membrane oxygenation in patients with severe respiratory failure from COVID-19. *Intensive Care Med* 47:208–221. <https://doi.org/10.1007/s00134-020-06331-9>
 168. Chiu L-C, Chuang L-P, Leu S-W et al (2021) Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome: propensity score matching. *Membranes (Basel)* 11:393. <https://doi.org/10.3390/membranes11060393>
 169. Whebell S, Zhang J, Lewis R et al (2022) Survival benefit of extracorporeal membrane oxygenation in severe COVID-19: a multi-centre-matched cohort study. *Intensive Care Med* 48:467–478. <https://doi.org/10.1007/s00134-022-06645-w>
 170. Hajage D, Combes A, Guervilly C et al (2022) Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: an emulated target trial analysis. *Am J Respir Crit Care Med* 206:281–294. <https://doi.org/10.1164/rccm.202111-2495OC>
 171. Urner M, Barnett AG, Bassi GL et al (2022) Venovenous extracorporeal membrane oxygenation in patients with acute covid-19 associated respiratory failure: comparative effectiveness study. *BMJ* 377:e068723. <https://doi.org/10.1136/bmj-2021-068723>
 172. Combes A, Brodie D, Aissaoui N et al (2022) Extracorporeal carbon dioxide removal for acute respiratory failure: a review of potential indications, clinical practice and open research questions. *Intensive Care Med* 48:1308–1321. <https://doi.org/10.1007/s00134-022-06796-w>
 173. Bein T, Weber-Carstens S, Goldmann A et al (2013) Lower tidal volume strategy (≈ 3 ml/kg) combined with extracorporeal CO₂ removal versus 'conventional' protective ventilation (6 ml/kg) in severe ARDS. *Intensive Care Med* 39:847–856. <https://doi.org/10.1007/s00134-012-2787-6>
 174. McNamee JJ, Gillies MA, Barrett NA et al (2021) Effect of lower tidal volume ventilation facilitated by extracorporeal carbon dioxide removal vs standard care ventilation on 90-day mortality in patients with acute hypoxemic respiratory failure: the REST randomized clinical trial. *JAMA* 326:1013–1023. <https://doi.org/10.1001/jama.2021.13374>